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ABSTRACT 
DANIEL M. ROTROFF: Endocrine Disrupting Potential of Environmental Chemicals 
Characterized by High-Throughput Screening 
(Under the direction of Dr. David J. Dix) 
 
Over the past 20 years, an increased focus on detecting environmental chemicals that 
pose a risk of endocrine disruption and congressional legislation have driven the creation of 
the U.S. EPA Endocrine Disruptor Screening Program (EDSP). Several thousand chemicals 
are subject to the EDSP, which will require millions of dollars and decades to process using 
current test batteries. In order to identify opportunities for increased chemical throughput, we 
initially investigated how well EPA ToxCast in vitro high-throughput screening (HTS) 
assays relevant for estrogen, androgen, steroidogenic, and thyroid disrupting mechanisms 
could identify compounds relative to in vitro and in vivo data collected from studies related 
to the EDSP Tier 1 screen. An iterative, balanced optimization model was implemented and 
indicated that ToxCast HTS assays measuring estrogen receptor (ER) and androgen receptor 
(AR) activation classify compounds with estrogenic and androgenic activity in guideline 
studies with a high degree of accuracy, respectively. The ER signaling pathway involves a 
wide array of molecular initiating events and cellular processes. This dissertation examined 
whether active chemicals in ToxCast ER transactivation assays could indicate chemical-
induced upregulation of the ER pathway through ligand binding leading to induced changes 
in T47D growth kinetics. Considering the complex set of ER in vitro assays in toto increased 
the overall sensitivity of detection for ER reference chemicals. In addition, this research 
 iv
highlighted important aspects of the biological response such as non-ER specificity in the 
cell growth assay. These nuances are likely important considerations for the construction of a 
predictive model. In effort to accurately predict the estrogenic potential of environmental 
chemicals in a high-throughput format, multiple orthogonal in vitro ER assays were used to 
develop a predictive model for ~2000 chemicals. Model results indicate a high degree of 
predictivity for both the uterotrophic in vivo assay and ER reference chemicals.  The 
information provided by the model will aid in understanding how environmental chemicals 
contribute to endocrine-related human health consequences and predict the estrogenic 
potential of chemicals through the use of in vitro assays, limiting the need to run more costly 
and animal-intensive in vivo bioassays. 
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CHAPTER 1 
INTRODUCTION 
Endocrine Physiology 
 The endocrine system consists of glands that secrete hormones that regulate and 
influence almost every organ and cell type. These hormones are secreted into the blood 
stream and activate signaling cascades to regulate and maintain a diverse set of biological 
functions. The various functions include glucose metabolism, sexual differentiation, bone 
density, blood pressure, and digestion (Cooper and Kavlock 1997; Dupont et al. 2000; Lodish 
et al. 2009; de Mello et al. 2011; Ng et al. 2001).  
 
The endocrine system is commonly described in three axes: the hypothalamic-
pituitary-gonadal (HPG) axis, the hypothalamic-pituitary-adrenal (HPA) axis, and the 
hypothalamic-pituitary-thyroid (HPT) axis (Figure 1.1). These physiological axes represent 
three different feedback systems and involve multiple, highly interrelated, signaling 
pathways occurring between key organs to maintain homeostasis of bodily functions. The 
ultimate control center, the hypothalamus, secretes gonadotropin-releasing hormone (GnRH), 
growth hormone-releasing hormone (GHRH), thyrotropin-releasing hormone (TRH), 
corticotrophin-releasing hormone (CRH), and other important determinants of endocrine 
function into the hypophyseal portal system (Jessop 1999; Knol 1991). These hormones act 
directly on the anterior pituitary to stimulate its release of gonadotropins, growth hormone, 
and thyroid stimulating hormone (TSH), respectively (Fox 2004).  
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Gonadotropins are a group of anterior pituitary hormones that include follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) (Figure 1.1a) (Fox 2004). These 
peptide hormones, along with the steroid hormones estrogen and progesterone, control the 
ovarian cycle in females (Fox 2004). In males, FSH stimulates primary spermatocytes to 
undergo meiosis and LH triggers testosterone production (Walker and Cheng 2005). Gonadal 
stimulation by FSH induces the release of the peptide factor ‘inhibin’, which in turn acts back 
on the anterior pituitary to inhibit FSH production. Increases in serum concentration of sex 
steroids (estrogen, testosterone) suppress GnRH secretion by the hypothalamus and FSH and 
LH secretion by the anterior pituitary gland.  The coordination of these hormones in both 
positive and feedback circuits is necessary for proper homeostasis of the HPG axis (Fox 
2004). 
 The HPT axis is primarily involved in regulating growth, metabolism and 
development (Figure 1.1b) (Zoeller et al. 2007). Thyroid follicular cells, transport iodine and 
secrete triiodothyronine (T3) and thyroxine (T4) via thyroid peroxidase (TPO),when 
stimulated by TSH from the anterior pituitary. The main role of TSH is to free T3 and T4 
from thyroglobulin so they can be released into the blood stream (Zoeller et al. 2007). T3 is 
critical to fetal neurodevelopment, and postnatally helps to regulate metabolism and cardiac 
output (Bernal, 1984; Oppenheimer and Schwartz, 1997). T3 and T4 work synergistically 
with growth hormone (GH) and consequently (an inhibitor of GH) to further down-regulate 
TSH secretion from the anterior pituitary (Figure 1.1b) (Zoeller et al. 2007).  
 Hormones produced through activating the HPA axis are necessary for reproductive 
health, glucose metabolism, and blood pressure (Figure 1.1c) (Fox 2004). Hypothalamic 
CRH secretion stimulates ACTH release from the anterior pituitary. The ACTH target tissue 
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is the adrenal cortex. Its outer zone (zona glomerulosa), middle zone (zona fasciculate), and 
inner zone (zona reticularis) produce different hormones in response to ACTH stimulation 
and all three are synthesized from cholesterol. Although not entirely distinct from one 
another, the zona glomerulosa primarily secretes mineralocorticoids such as aldosterone (Fox 
2004). Aldosterone regulates blood pressure through renal retention of sodium and water 
(Brewster and Perazella 2004). The zona fasciculata and reticularis are responsible for 
synthesizing the glucocorticoids cortisol and corticosterone, which upregulate 
gluconeogenesis and lypolysis for bioenergy production (Fox 2004). The two innermost 
zones are also responsible for synthesizing androstenedione, a precursor molecule to both 
testosterone and estrogen. The enzymes 17β-hydroxysteroid-dehydrogenase and aromatase 
(CYP19) convert androstenedione to testosterone and estradiol, respectively. These 
enzymatic conversions typically occur in the testis and ovary, respectively; however, 
aromatase is also expressed in non-gonadal tissues such as fat, which can further promote 
estradiol synthesis (Simpson and Davis 2001).  Increased serum concentrations of these 
hormones have the ability to down-regulate CRH release from the hypothalamus and ACTH 
from the anterior pituitary (Figure 1.1c).  
 
Human Endocrine Disruption and Pathology 
The endocrine system is integral to many physiological functions. Disruption of the 
endocrine system can have varying severity depending on the etiology. Many endocrine 
pathologies occur in the form of neoplasms or cellular hyperplasia, causing overproduction 
of that tissue’s hormone. They also occur in the form of atrophic conditions preventing the 
appropriate levels of hormone to be secreted. Because homeostatic endocrine processes are 
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highly interrelated, treating one type of endocrine deficiency can have unintended 
consequences on another endocrine process. For example, hyperaldosteronism can be a result 
of adrenal hyperplasia or adrenal carcinoma and can cause increased water and sodium 
retention resulting in subsequent hypertension (Calhoun et al. 2002; Lindsay and Atkinson 
2009).  One treatment option for hyperaldosteronism is to administer a mineralocorticoid 
antagonist, such as spironolactone; however, this drug is a weak androgen receptor (AR) and 
glucocortocoid receptor (GR) antagonist that also displaces testosterone and estradiol from 
sex hormone binding globulin. Manifestations of this disruption in males is include 
gynecomastia and testicular atrophy, and in females altered menstruation (Lubbos HG 1998; 
de Souza et al. 2010).   
Epidemiological evidence suggests an increasing incidence of poor semen quality, 
testicular cancer, and other male reproductive disorders including undescended testis 
(cryptorchidism) and urethral fusion defects (hypospadias) (Auger et al. 1995; Carlsen et al. 
1992; Skakkebaek et al. 2001). Cryptorchidism and hypospadias are common human 
malformations with an incidence in liveborn infants of 2-9% and 0.2-1%, respectively 
(Toppari et al. 2010).  The collective term for developmental defects of the male tract is 
Testicular Dysgenesis Syndrome (TDS). TDS is diagnosed by the co-occurrence of poor 
semen quality, testicular germ line tumors, hypospadias, and/or cryptorchidism in various 
combinations (Skakkebaek et al. 2001). Studies have demonstrated associations of increased 
incidences of TDS with exposure to certain environmental chemicals (Toppari et al. 2010).  
The evidence is unequivocal that certain pharmaceuticals have potential to disrupt 
endocrine function and may lead to reproductive abnormalities. One example, 
diethylstilbesterol (DES), was first applied as a cattle feed supplement and later prescribed to 
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women to lower the risk of miscarriage (Palmlund et al. 1993). Approximately 5 million 
women were prescribed DES during pregnancy in the United States alone (Palmlund et al. 
1993). DES not only failed as a therapeutic for spontaneous pregnancy loss but also led to 
premature labor and neonatal death. Some females exposed in utero displayed increased 
incidences of cervical and vaginal clear cell adenocarcinoma, vaginal adenosis, and genital 
tract abnormalities (Palmlund et al. 1993). Males exposed in utero demonstrated increased 
incidences of cryptorchidism, hypospadias, infertility, poor semen quality, and rete testis 
adenocarcinoma among other disorders (Toppari et al. 2010). 
Some environmental chemicals have been shown to interfere with male reproductive 
development through endocrine mechanisms. Vinclozolin is one example. This fungicide was 
used to treat many types of berries, grapes, and other crops (U.S. EPA 2000). Current 
exposures to vinclozolin are considered to be very low after the voluntary termination of uses 
and import tolerances (U.S. EPA 1998). Its antiandrogenic properties are well characterized 
in both in vitro and in vivo rodent bioassays. Vinclozolin is a weak AR antagonist but is 
quickly metabolized in serum to active metabolites, M1 and M2 (Sierra-Santoyo et al. 2012). 
Numerous studies demonstrated the ability of vinclozolin to compete with testosterone and 
DHT for AR (Fang et al. 2003; Kojima et al. 2003; Scippo et al. 2004). In vitro 
transactivation assays have also demonstrated that M1 and M2 can downregulate 
transcriptional activation of AR (Freyberger et al. 2010; Kojima et al. 2003; Vinggaard et al. 
2005).  Male rats exposed to vinclozolin in utero have higher incidences of vaginal pouch, 
cryptorchidism, seminiferous tubular atrophy, nipple retention, hypospadias and reduced 
anogenital distance (Gray et al. 1994). Peripubertal male rats given vinclozolin experienced 
delays in sexual maturation, such as increased age at preputial separation. Although studies 
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testing vinclozolin for antiandrogenic and TDS phenotypes have been conducted using 
animal studies, a mode-of-action framework created to determine the relevance of these 
animal effects for human risk assessment identified the vinclozolin-induced malformations of 
the male reproductive tract as being highly plausible in humans (Kavlock and Cummings 
2005).  
 
Environmental Impact of Endocrine Disruption 
Endocrine disruption not only poses a risk to human health, but also poses a 
significant risk to environmental health (Caliman and Gavrilescu 2009; Kiesecker et al. 
2001). Furthermore, the environment often serves as a sentinel for potential human health 
hazards (Caliman and Gavrilescu 2009). Pesticide runoff or drift from crops, as well as 
pharmaceutical presence in wastewater have potential for significant adverse health effects 
on wildlife (Sparling and Fellers 2009; Tavera-Mendoza et al. 2002).  An active area of 
research for the impact of environmental chemicals on wildlife is the significant global 
decline of amphibians (Hof et al. 2011).   
Atrazine, for example, is a common chlorotriazine herbicide that has been detected 
frequently in U.S. surface waters and drinking water sources (U.S. EPA 2011b). Many 
studies have been conducted implicating atrazine’s potential as an endocrine disrupting 
chemical (EDC) by altering the HPG axis (Cooper et al. 2000; Hayes et al. 2003; Stoker et al. 
2000; U.S. EPA 2011b). Several studies demonstrated a link between atrazine exposure in 
various strains of rats with reduced serum testosterone, effects on male accessory tissues, and 
altered spermatogenesis (Abarikwu et al. 2010; Kniewald et al. 2000; Stoker et al. 2000). 
Although the mechanism by which atrazine suppresses testosterone is not known, evidence 
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suggests that decreases in the secretion of LH is the primary cause of testicular 
consequences.  
Atrazine is not believed to directly affect LH, because LH was induced in atrazine-
treated rats administered GnRH. This implies an alternate neuroendocrine mechanism 
(Cooper et al. 1996, 2000). A study conducted by Shafer et al. supported this hypothesis by 
showing that atrazine and cyanazine non-competitively inhibited the binding of a 
benzodiazepine to GABAA receptors (Shafer et al. 1999).  Furthermore, GABAA receptors 
have been shown to be important regulators of GnRH release (Terasawa 1998). Leydig cells 
respond to LH by synthesizing testosterone, which can then be converted to 
dihydrotestosterone (DHT) by 5α-reductase. Additional data suggests that atrazine can inhibit 
the conversion of testosterone to DHT by 5α-reductase (Simic et al. 1991). Although the 
effects on 5α-reductase may not be the primary mechanism for alterations in 
spermatogenesis, the important role DHT plays in the development and maintenance of 
tissues such as the prostate and seminal vesicles may exacerbate the effects from LH 
suppression (Cai et al. 1994).  
The U.S. EPA currently estimates the aquatic ecosystem level of concern (LOC) for 
atrazine as approximately 10 ppb (10 µg/L) over a 60-day period (U.S. EPA 2009a). 
However, in some rivers concentrations of atrazine have reached 21µg/L and areas near 
fields utilizing atrazine can reach 250 µg/L (Solomon et al. 2009). Studies have shown 
effects on amphibian larval development and demasculinization after atrazine exposures. A 
study by Tavera-Mendoza et al. (2002) found that exposures of 21 µg/L resulted in decreased 
testicular volume in male amphibians and testicular aplasia in tadpoles. Another study by 
Hayes et al. (2002) exposed amphibian larva to levels of (0.01-200 ppb), but found no effects 
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on time to metamorphosis or mortality; however, effects at all doses higher than .01 ppb 
produced multiple gonads or were hermaphrodites with multiple testes and ovaries, and 
displayed decreased plasma testosterone.  
 Environmental exposures of EDC’s that play a role in the decline of wildlife 
amphibian populations may also be relevant for human health. Cragin et al. (2011) provided 
epidemiological evidence of statistically significant trends in reports of irregular menstrual 
cycle lengths in areas with high levels of atrazine drinking water contamination versus 
women residing in areas with low levels of atrazine contamination. In order to maintain 
healthy wildlife areas and prevent adverse human health effects from environmental 
exposures to EDC’s, it is critical that a complete characterization of the potential interactions 
pharmaceuticals and environmental chemicals could have on healthy endocrine physiology is 
performed. 
 
Endocrine Disruptor Screening 
Environmental chemicals such as bisphenol-A, phthalates, and parabens have 
exhibited potential to interfere with the endocrine system and are nearly ubiquitous in the 
environment. These compounds have commercial applications in food and drink packaging, 
polycarbonate plastics, detergents, polystyrene tubes, cosmetics, and shampoos (Calafat et al. 
2005; Smith et al. 2012; Sonnenschein and Soto 1998; U.S. HHS 2008). The potential for 
adverse health and environmental effects due to EDC exposure has lead to increased public 
awareness of safe products and increased pressure for political and regulatory action.  
The Federal Food, Drug, and Cosmetic Act (FFDCA) was passed in 1938 following 
the death of more than 100 people in what is known as The Elixer Sulfanilamide Incident of 
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1937 (Ballentine 1981). The incident occurred after the drug, sulfanilamide, was exposed 
with diethylene glycol. Subsequently, Congress passed the FFDCA and provided authority to 
the Food and Drug Administration (FDA) to regulate safety requirements for food, drugs and 
cosmetics (Ballentine 1981). In 1996, the Food Quality Protection Act (FQPA) and the Safe 
Drinking Water Act (SDWA) were passed. These two acts amended the FFDCA, and 
required that the U.S. EPA determine whether certain substances may have an effect in 
humans similar to a naturally occurring estrogen, or other endocrine related effects (21 
U.S.C. 346a 1996; U.S. Public Law 1996). To address these requirements, the EPA formed 
the Endocrine Disruptor Screening Program (EDSP) (www.epa.gov/endo/) (U.S. EPA 
2012a).  
EDSP requires that chemical manufacturers provide data from specific in vitro and in 
vivo assays while following strict guidelines to insure testing is performed consistently and 
reliably. EDSP consists of two tiers of testing. The first is composed of in vitro and in vivo 
assays designed to measure effects on estrogenic, androgenic, thyroid and steroidogenesis 
modes of action (MOA). A weight-of-evidence approach has been proposed as a decision 
making tool for determining what compounds will go from tier 1 (T1S) to tier 2 (T2S). The 
selection of assays in T2S has not been finalized, but the assays under consideration include 
more resource intensive assays such as the mammalian two-generation, avian two-generation, 
and others (U.S. EPA 2012a).    
  Under the FFDCA and SDWA amendments of 1996, approximately 10,000 chemicals 
are subject to testing by EDSP (U.S. EPA 2012a). Since the inception of EDSP, however, 
orders for testing only about 200 chemicals have been issued. Decisions on how chemicals 
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will be selected for T2S testing or what assays will be included in T2S testing remain to be 
seen.  
In an effort to increase throughput, the EPA’s EDSP21 project is aiming to use high-
throughput in vitro and in silico approaches to prioritize which chemicals should be tested in 
T1S first (U.S. EPA 2011a, 2012b). Goals of the EDSP21 work plan include replacing 
certain resource intensive T1S assays within the next five years and full replacement of T1S 
with high-throughput in vitro and in silico assays as a long-term goal (U.S. EPA 2011a). In 
order to meet these goals, methods for validating in vitro assays, and models that combine in 
vitro assays to optimize for predictive capabilities must be developed.  
 The U.S. EPA National Center for Computational Toxicology’s ToxCastTM program 
and the cross-agency Tox21 program are currently screening chemicals in hundreds of high-
throughput in vitro assays, some of which are endocrine related (Kavlock et al. 2012). The 
current ToxCast and Tox21 chemical libraries represent approximately 17% and 53% of the 
EDSP chemical universe, respectively. Successful predictive models have been developed 
using the assays and chemicals from these projects (Judson et al. 2012; Martin et al. 2011; 
Sipes et al. 2011). Furthermore, tools for prioritizing chemicals have also been developed 
using these data sets (Reif et al. 2010). Therefore, it stands to reason that these programs are 
uniquely poised to develop predictive models for endocrine related targets that would be 
valuable in augmenting the EDSP screening effort.   
 
Computational Toxicology and Alternatives to Traditional Test Methods 
 Although the study of toxic substances has been ongoing for centuries,  a rapid 
expansion of the chemical landscape  has forced toxicology into a new dimension. Many 
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thousands of chemicals are now being manufactured, and due to the backlog of chemicals in 
regulatory testing, the majority of chemicals have yet to undergo full toxicological evaluation 
(Judson et al. 2009). Due to ethical limitations, toxicologists have always had to rely on 
extrapolating toxicities observed in animals to potential adverse health effects in humans 
with an equivalent exposure. Because animals are intrinsically different than humans, this 
process can be quite uncertain. Furthermore, deciding on an appropriate animal model or 
reconciling contradictory results between animal models can further pose a challenge for 
decision makers.      
 Today, toxicology finds itself in the midst of a paradigm shift. Traditionally, the 
primary source of data relating chemical exposures to adverse outcomes in humans came 
from in vivo animal models. Study designs using mostly rats, mice, and rabbits are used for 
testing chemicals for carcinogenic, reproductive, developmental, chronic, and acute health 
effects (Knudsen et al. 2009; Martin et al. 2009b, 2009a). In addition to the difficulty of 
extrapolating human health effects from animal tests, these studies can require up to two 
years and $2 million for an individual chemical. Although these studies offer the advantage 
of an intact organism to test for toxicity, they often require high doses and overt effects 
before a chemically induced effect can be observed.  
 Recent advances in in vitro biotechnology can now help meet the need to test more 
chemicals and provide information about their interactions with many human molecular 
targets. The need for better mechanistic understanding and species extrapolation has led to 
development of technologies such as toxicogenomics. Sets of genes that are activated or 
suppressed after a toxic insult can be grouped and used to phenotypically anchor genetic 
changes to more traditional toxicological endpoints (Thomas et al. 2001). This is useful 
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because transcriptional activation/suppression is thought to be one of the earliest cellular 
changes in an adverse response. The ability to sensitively measure these changes can allow 
for experiments to be conducted at more realistic exposure levels than many traditional 
toxicology tests, which rely on measurements of overt toxicity from high doses (Nuwaysir et 
al. 1999). However, this technology comes with certain disadvantages and challenges. One of 
the disadvantages is that not all genes perturbed after a chemical exposure may be involved 
in the toxicity pathway, leading to results that can be difficult to interpret (Green et al. 2007). 
Furthermore, it is difficult to distinguish the primary genes regulated by a chemical versus 
the less-specific secondary or tertiary gene changes and these results can vary by assay 
technology and laboratory practice (Beyer et al. 2007). 
   
Many studies have attempted to use in vitro assay data to demonstrate associations 
with human and rodent adverse health effects using a wide variety of methods and 
informatics techniques. Studies that use machine learning algorithms with data covering large 
amounts of chemical and biological space that do not incorporate prior biological knowledge 
show poor predictive capabilities (Benigni et al. 2010; Thomas et al. 2012).  On the other 
hand, methods which group assays based on biological pathways have shown promising 
potential to predict in vivo outcomes (Judson et al. 2012; Martin et al. 2011; Sipes et al. 
2011). It is important to remember that many of the in vitro assays used in these models are 
conducted using human cell lines. In the near future, predictive models from in vitro assays 
may be used to prioritize chemicals for further testing with the long term goal of replacing 
the more resource intensive assays.   
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The ToxCast program and the cross-agency Tox21 program are currently evaluating 
the use of high-throughput in vitro assays to prioritize chemicals for testing in more 
traditional toxicology bioassays (Judson et al. 2010; Kavlock et al. 2012). The enormous 
influx of data provided by these technologies on thousands of chemicals has many 
advantages, but also comes with certain challenges. Not the least of which is the integration 
of these molecular initiating events with new and existing in vivo data, and relating these 
effects to relevant human outcomes (Collins et al., 2008; Kavlock et al., 2009; Judson et al., 
2010). 
In an attempt to identify informative endocrine-related in vitro assays, many studies 
demonstrate their utility by comparing the results to known reference compounds or compare 
the results to other in vitro assay results (Kloas et al. 1999; Soto et al. 1995). However, until 
now no resource for comparing a large number of chemicals for in vitro to in vivo endpoints 
was available for endocrine-specific targets. The present body of work develops a library of 
quantitative in vivo and in vitro data from a wide variety of endocrine studies, including 
validated study designs (as described in Chapter 2).  This dataset provides the first resource 
for phenotypically anchoring endocrine related assays for a large set of chemicals and the 
following work described in Chapter 2, tests whether HTS assays, relevant for key endocrine 
targets, can classify chemicals consistently with guideline endocrine studies captured in this 
dataset. 
 
Estrogen Signaling Pathways in Predictive Toxicology 
 Testosterone and androstendione are synthesized in the adrenal cortex of males and 
females from a cholesterol precursor. These two androgens can be converted to endogenous 
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estrogens, 17β-estradiol and estrone, by the aromatase enzyme (CYP19A1). Aromatase is 
present in a wide variety of tissues including ovaries, placenta, brain, and adipose tissue 
(Simpson and Davis 2001; Simpson et al. 1994). Circulating estrogen can bind and modulate 
the ER which in part regulates sexual differentiation, bone density, fertility, cell proliferation, 
and inflammatory responses (Harnish 2006; Kobayashi et al. 1996; Krege et al. 1998).  
Although there are still many unanswered questions regarding the ER signaling 
pathway, the information gained from understanding the relationship between chemical 
behaviors and endogenous hormone structure has led to the development of successful 
pharmaceutical compounds(Gabriel and Jatoi 2012; O’Regan and Jordan 2001). These drugs 
are most often used to treat various forms of ER-responsive cancers, although they can also 
be used to treat individuals with hormone insufficiency as well. The success of these 
chemotherapeutics has been dampened by discovery of side-effects, such as increased 
incidences of endometrial cancer after tamoxifen treatment (Fisher et al. 1994). These 
discoveries demonstrate the complexities of ER signaling, and contributed to the 
understanding that some chemicals that target ER have opposite behaviors in different 
tissues. These compounds are called selective estrogen receptor modulators (SERM) (Lewis 
and Jordan 2005; Tee et al. 2004).   
Two ER subtypes are known: ERα and ERβ. The ligand binding domain (LBD) 
between the two receptors is only 59% homologous; however, the activation function 2 (AF-
2), where the ligand binds, is almost identical with only two amino acids differing between 
the two subtypes. The DNA binding domain (DBD) differs by only 3% (Shanle and Xu 
2011). In addition, the activation function 1 (AF-1) domain can regulate transcriptional 
activation independently of ligand binding. The AF-1 domain shares only 18% similarity 
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between the two subtypes. Therefore, many ligands that can bind both receptor subtypes may 
do so with varying affinities or cellular consequences. Furthermore, ERα and ERβ are 
expressed at different basal levels in different tissues. With only a 17% overlap in the genes 
regulated by both receptors (Tee et al. 2004), this expression implies differential biological 
effects to either receptor subtype. Finally, many different cofactors can bind to further 
regulate these differential responses and themselves vary in cellular concentration and 
cellular expression (Shanle and Xu 2011). As such, it is not surprising that slight variants in 
chemical structure can still engage the ligand binding domain (LBD) but invoke distinct 
responses. 
Steroid hormones produced by the adrenal cortex and the gonads are synthesized 
from a cholesterol precursor. For that reason, steroid hormones share a similar structure with 
three 6-carbon rings and one 5-carbon ring (Fox 2004). Xenobiotic compounds known to 
target ER, such as DES, genestein, ICI 182,780, o,p’-DDT, p,p’-DDT, and tamoxifen, have 
structural similarity to 17β-estradiol (they all have at least three 6-carbon rings). However, 
these compounds differ from one another by potency and pharmacological activity as 
agonists, antagonists, or both. Part of this differential activity may be due to the presence of 
side-chains or functional groups that protrude from the ligand binding pocket (Wu et al. 
2005). An AF-2 H12 motif typically wraps around the ligand inside of the binding pocket, 
and the side-chain or functional group present on a particular chemical structure can 
sterically alter the H12 motif to decrease ERα stability and, in turn, alter the binding affinity 
to coactivators and corepressors at the AF-2 cleft (Wu et al. 2005). ICI 182,780, a pure ER 
antagonist, has a bulky side-chain that blocks the association between H12 and LBD. 
Tamoxifen, an antagonist in mammary tissue and an agonist in uterine tissue, has a shorter 
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side-chain that allows H12 to more closely associate with the LBD (Wu et al. 2005). Many 
estrogens are structurally similar; however, small changes in chemical structure can 
drastically alter the phenotypic response. 
 Alterations in receptor mediated activity are responsible for the different phenotypic 
profiles observed with various estrogenic compounds. Characteristically, SERMs exhibit 
‘partial agonist’ ER activity. These compounds compete for the ligand binding domain and 
will result in a reduction in overall signal by ER (Zhu 2005). However, if no full agonist is 
present, these SERM compounds will cause an overall increase in signal by ER.  For 
example, tamoxifen given to premenopausal women can accelerate osteoporosis by 
competing with endogenous 17β-estradiol. However, tamoxifen can help prevent bone loss in 
postmenopausal since endogenous levels of 17β-estradiol are greatly reduced (Dardes et al. 
2002).   
Another contributor to the differential responses caused by xenoestrogens results 
from the ratio of ERα/ERβ. Tissues with high ERα/ERβ ratios, such as breast tissue, 
proliferate when exposed to estrogens. Other tissues, such as the colon, have a low ERα/ERβ 
ratio and experience suppressed growth when exposed to estrogens (Fiorelli et al. 1999).   
Endocrine disrupting compounds that operate through receptor-mediated mechanism(s) tend 
to have common chemical structure characteristics. The knowledge of structural 
characteristics and selective activity of ER has resulted in effective pharmaceutical SERMs; 
however, because the slight variations among these chemical structures alter receptor activity 
and cellular consequences, and because downstream effects vary by cell state and tissue type, 
less is known about the potential for environmental chemicals to act as SERM compounds.   
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Predictive Modeling of Endocrine Disruptors 
With the growing number of manufactured chemicals, there is an increasing need for 
high-throughput and computational techniques to test chemicals for their potential to cause 
adverse health effects. Traditional regulatory toxicology tests are too expensive and are too 
slow to effectively screen all necessary chemicals. Biotechnology has improved significantly 
in the past 15 years, and in vitro assays are now capable of testing many human molecular 
targets with known toxicological implications for thousands of chemicals (Kavlock et al. 
2012). These assays must be qualified as to their predictive capabilities in terms of sensitivity 
(identifying positives) and specificity (differentiating positives from negatives) in order to be 
applicable for chemical prioritization in lieu of a traditional low-throughput regulatory 
paradigm. 
In order to successfully predict and model biological endpoints, data is needed to 
anchor and validate toxicities predicted by computational toxicology. Although a recent 
transformation for the field of regulatory toxicology, high-throughput assays and predictive 
models have been used extensively in drug screening (Bibette 2012).  For example, based on 
rodent 28-day repeat-dose studies using 15 male Sprague–Dawley rats treated with known 
renal toxicants, Fielden et al. (2005) demonstrated a toxicogenomic signature of 35 genes 
that correctly classified 76% of compounds that caused renal tubular degeneration. As with 
any in vivo bioassay or in vitro assay, there are distinct advantages and limitations that must 
be considered when extending a classification schema into a predictive signature. Genomic 
perturbations may classify compounds correctly, but the target may not be directly related to 
the toxicological endpoint. The gene may be activated or deactivated by a secondary 
mechanism which might limit its ability to predict the toxicological endpoint.   
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Quantitative structure activity relationship (QSAR) models that make use of chemical 
structure to predict biological outcomes have historically shown marginal success for some 
outcomes but become less effective for toxicities of reproduction and development. One 
reason for this may be a limited capacity to reproduce the entire cellular and mechanistic 
complexity of developmental and reproductive processes. An integrative approach with 
QSAR and in vitro assays may, however, improve certain predictions of in vivo adverse 
effects, including those relevant for reproductive and developmental toxicity (Sedykh et al. 
2011; Zhu et al. 2008). Because the endocrine system is highly complex and interconnected 
with many different targets capable of affecting steroid hormone production and function, it 
is not plausible that any single assay would accurately predict the endocrine disrupting 
potential across a large and diverse chemical landscape. One method of addressing these 
limitations is to use an integrative approach of developing models composed of multiple 
assays for each endocrine MOA. The work presented in this dissertation aims to combine 
multiple in vitro assays into a model capable of detecting compounds that will interfere with 
the estrogen MOA.Ultimately combining multiple models across each relevant endocrine 
MOA may provide the greatest opportunity for comprehensively detecting endocrine 
disrupting chemicals.   
Computational models capable of predicting chemical impacts on steroid biosynthesis 
using the adrenocortical cell line, H295R, have been developed. A study by Breen et al. 
(2010) demonstrated that a computational model of the steroidogenesis pathway could 
accurately reproduce the effects of CYP11β-hydroxylase inhibitor, metyrapone. Additional 
efforts to make the model generalizable, and a larger validation set, are needed to qualify this 
type of predictive model for broader translation into regulatory toxicology. An in vitro 
 19
screening assay in H295R cells measuring effects on estrogen and androgen synthesis is 
already included in the EDSP T1S, but in a 24 well format (U.S. EPA 2012a) thus limiting 
this to a medium throughput platform. The ToxCast program is currently exploring methods 
for a high-throughput version of this assay.  
 For detecting chemicals with the potential to interact with ER, the EPA has 
developed the estrogen receptor QSAR/rule-based expert system (ERES). ERES uses 
structural characteristics, ER binding affinity and fish vitellogenin as indicators of estrogenic 
activity, along with certain decision making criteria (U.S. EPA 2009b). Although this 
approach may be useful for prioritizing or screening chemicals for estrogenic activity, there 
are several shortcomings highlighted by the 2009 EPA Scientific Advisory Panel.  1) The 
model was constructed using pesticide inert ingredients and antimicrobial pesticides that may 
not be applicable to other chemical domains. 2) The ER binding assay does not distinguish 
agonist from antagonist, or ERα from ERβ activity. 3) There are examples of non-receptor 
mediated estrogenic activity that may go undetected in this model. 4) Lastly, there was no 
automatic approach to deriving decision rules (U.S. EPA 2009b).  
One method for combining in vitro assays to predict reproductive toxicants was 
explored by the 6th European Union’s ReProTect project (Schenk et al. 2010). This study 
investigated this approach to determine the feasibility of developing an integrated testing 
strategy for reproductive and developmental toxicants. Ten blinded chemicals with well 
characterized reproductive profiles were tested in 14 in vitro assays. The two major 
requirements for chemical selection included well characterized in vivo effects and no 
CYP450-mediated metabolic activation. The assays selected were designed to target male 
and female infertility, implantation, or embryonic development. The activity concentration at 
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50% response (AC50) was calculated and ranked in comparison to reference chemical 
responses in each assay. The entire study was conducted in a double-blind fashion, and the 
chemicals were only revealed after running the model. Effect types were split into three 
groups (female fertility, male fertility, and developmental toxicity). Overall, the 10 chemicals 
in the 3 groups resulted in 26/30 correct classifications. The results indicate that for this small 
set of chemicals, the rankings are highly correlated with their known toxicological profile 
(Schenk et al. 2010). This study successfully demonstrated that models based on combining 
in vitro assays can correctly classify compounds that interfere with complex mechanisms of 
reproduction and fetal development in vivo.    
In order for the long-term goal of replacing in vivo assays with in vitro and in silico 
based approaches to be successful, a method for deriving human oral equivalent doses based 
on activity concentrations will be needed. A computational approach for this was developed 
in Rotroff et al. (2010) and was later applied to a larger chemical library in Wetmore et al. 
(2012). This approach uses human serum albumin and metabolic clearance to derive 
mg/kg/day conversion factors for in vitro measures of bioactivity. Comparisons to published 
PBPK models demonstrated that the oral equivalent values were reasonably concordant 
(Rotroff et al. 2010; Wetmore et al. 2012). Additional work by Hays and Aylward (2011) 
demonstrated a method to derive an estimated serum concentration for doses for which 
adverse effects were observed in rodent studies. Both methods can be used to enhance the use 
of assays for human health effects, but the model described by Hays and Aylward (2011) will 
create an equivalent for overt toxicity; whereas the model described by Rotroff et al. (2010) 
derives equivalents for molecular events.  
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A wide variety of methods and technologies exist for developing predictive models. If 
modeling efforts are to succeed for endocrine screening, data to anchor predictions will not 
only need to be high quality, but will need to exist for enough chemicals to determine the 
predictive capability of the model. This can be challenging since there are limited chemicals 
for which testing has been completed relative to the numbers screened in high-throughput 
efforts. Previous studies investigating a chemical response in multiple ER assays compare the 
assay responses equally and usually only take into account potency measurements (e.g. 
averaging AC50 values) (Kloas et al. 1999; Schenk et al. 2010).  
The methods outlined in this dissertation are novel in that they characterize 
endocrine-related in vitro assays by their entire concentration response, and take into account 
potency, efficacy, and uncertainty (as described in Chapter 4). Furthermore, the assays were 
previously characterized to determine causes for false positives and false negatives, and then 
combined in a manner that minimizes the impact of assay discrepancies (as described in 
Chapters 3 and 4). Strong reference chemicals are detected by most in vitro assays; however, 
accounting for sources of false positives and false negatives can help to address 
inconsistencies for weakly active or negative chemicals. The availability of large chemical 
libraries for both guideline in vivo studies and in vitro assays makes these comparisons 
possible. Chapter 2 aims to use a data-driven approach to identify candidate MOA for 
predictive modeling efforts, which subsequently will be used to prioritize chemicals for 
further endocrine-related testing. This study tests the hypothesis that a chemical’s in vitro 
activation of the estrogen or androgen receptor will indicate an increased likelihood of 
estrogen and androgen related effects in in vivo bioassays, respectively. Secondly, Chapter 3 
describes the evaluation of 1816 chemicals of environmental relevance for their potential to 
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alter cell growth kinetics through steroid hormone pathways in T47D cancer cells to test the 
hypothesis that compounds that activate ER transcription in the Attagene transactivation 
assay represent compounds upregulating the ER pathway through ligand binding and will 
result in compound-induced cellular changes in T47D growth kinetics. Finally, Chapter 4 
aims to develop a biologically-based model capable of determining estrogenic potential 
based on in vitro measurements from multiple components of the estrogenic pathway. This 
study tests the hypothesis that estrogen related disruption of reproductive health by 
environmental chemicals occurs by activating multiple molecular initiating events, these 
events are measurable in vitro and can be used to accurately determine estrogenic likelihood.   
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Figures 
Figure 1.1 (A) A schematic representation of the HPG axis. The hypothalamus triggers a series of hormones resulting in sex steroid 
production from the gonads. Increased serum levels inhibit the further production of sex steroids. (B) A schematic representation of 
the HPT axis. The hypothalamus, anterior pituitary, and thyroid gland regulate thyroid hormone (T3/T4) production. (C) The HPA 
axis is responsible for regulating a wide variety of hormones including corticosteroids, mineralocorticoids. The hypothalamus triggers 
a series of hormones resulting in sex steroid production from the gonads.  
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CHAPTER 2 
USING IN VITRO HIGH THROUGHPUT SCREENING ASSAYS TO IDENTIFY 
POTENTIAL ENDOCRINE-DISRUPTING CHEMICALS1 
 
Introduction 
 Endocrine hormones regulate a diverse set of physiological responses, some of which 
include sexual dimorphism, reproductive capacity, glucose metabolism, and blood pressure 
(Cooper and Kavlock 1997; Dupont et al. 2000; Lodish et al. 2009; de Mello et al. 2011; Ng et 
al. 2001). The many types of responses regulated by hormones makes them of particular concern 
for disruption by xenobiotics (Ankley and Giesy 1998; Colborn and Clement 1992; Soto and 
Sonnenschein 2010; Tilghman et al. 2010).Endocrine disruption can lead to many adverse 
consequences, some of which include altered reproductive performance and hormonally 
mediated cancers (Birnbaum and Fenton 2003; Kavlock et al. 1996; Soto and Sonnenschein 
2010; Spencer et al. 2012). Endocrine disruption can also have adverse effects on the fetus or 
newborn because of the delicate balance of hormones required during critical developmental 
windows (Bigsby et al. 1999; Chandrasekar et al. 2011; Cooper and Kavlock 1997; Mahoney and 
Padmanabhan 2010). For example, studies have demonstrated that thyroid hormone insufficiency 
during pregnancy may lead to adverse neurological outcomes in children (Haddow et al. 1999). 
                                                 
1
 Previously published as Rotroff DM, Dix DJ, Houck KA, Knudsen TB, Martin MT, McLaurin KW, Reif DM, 
Crofton KM, Singh AV, Xia M, Huang R, Judson RS. (2012). Using in Vitro High Throughput Screening Assays to 
Identify Potential Endocrine-Disrupting Chemicals. Environ Health Perspect. 2012 Sep 28. 
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The Federal Food, Drug, and Cosmetic Act (FFDCA , 1996), as amended by the Food 
Quality Protection Act (FQPA, 1996), and the Safe Drinking Water Act Amendments (SDWA, 
1996), requires the U.S. Environmental Protection Agency (EPA) to determine whether certain 
substances may have an effect in humans similar to that produced by a naturally occurring 
estrogen, or other such endocrine effects (FFDCA , 1996). In response, the U.S. EPA formed the 
Endocrine Disruptor Screening Program (EDSP) (U.S. EPA 2012a).  The EDSP is a two-tiered 
program that requires chemical manufacturers to submit or generate data on a suite of both in 
vivo and in vitro assays. The first phase of EDSP assays are designated as the Tier 1 screening 
(T1S) battery (U.S. EPA 2012b). These tests identify chemicals with the potential to interact 
with endocrine pathways or mechanisms, and focus on disruption of estrogen, androgen, and 
thyroid hormone pathways. Based on a weight-of-evidence approach, chemicals showing 
positive activity in T1S assays could then be subject to more complex Tier 2 tests (U.S. EPA 
2012a). The European Commission is continuing the implementation of the European Union’s 
Community Strategy for Endocrine Disrupters, which includes the establishment of a priority list 
of substances for further evaluation and assay development and validation (European 
Commission 2012). In addition, the European Commission is working toward defining specific 
criteria to identify endocrine disruptors within a legislative framework, drawing on current 
scientific opinion (Kortenkamp et al. 2011). 
The U.S. EPA estimates that the statutory requirements and discretionary authorities 
through passage of the FQPA and its amendments and the SDWA will require the EDSP to 
screen as many as 9,700 environmental chemicals. Generating this data required under the 
current testing guidelines will be expensive and time-consuming, and it will require significant 
animal resources (U.S. EPA 2011a). To date, chemicals have been nominated by the U.S. EPA 
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for EDSP T1S on the basis of exposure potential or registration status. Because of fiscal and time 
constraints, the U.S. EPA is considering using endocrine-related in vitro high throughput 
screening (HTS) assays and in silico models to prioritize chemicals for testing in T1S (U.S. EPA 
2011a). There has been a significant improvement in HTS technologies since the U.S. EPA 
began work on developing and implementing the EDSP. In 2007, the National Research Council  
Report Toxicity Testing in the 21st Century: A Vision and a Strategy (National Research Council 
2007) acknowledged these advances and recommended that the agency develop a strategy to use 
modern molecular-based screening methods to reduce, and ultimately replace, the reliance on 
whole-animal toxicity testing. The U.S. EPA’s ToxCast program (U.S. EPA 2012d), and the U.S. 
government’s cross-agency Tox21 program (U.S. EPA 2012c) are using HTS assays and 
developing computational tools to predict chemical hazard, to characterize a diverse set of 
toxicity pathways, and to prioritize the toxicity testing of environmental chemicals (Huang et al. 
2011; U.S. EPA 2012c). Included in these programs are assays that cover toxicity pathways 
involving estrogen, androgen, and thyroid hormone receptors, as well as targets within the 
steroidogenesis pathway. The current ToxCast chemical library covers approximately 17% of the 
chemicals subject to the EDSP, and the larger Tox21 chemical library covers approximately 53% 
of the chemicals subject to EDSP. Assay technologies include competitive binding, reporter 
gene, and enzyme inhibition assays. The comparison of HTS assays, endocrine-related modes of 
action (MOA) and EDSP T1S is shown in Figure 2.1. An endocrine MOA consists of a series of 
molecular initiating events relevant for estrogen, androgen, thyroid, or steroidogenic pathways. 
These assays do not represent their respective MOA in its entirety, but are used to detect 
chemicals capable of perturbing a particular MOA. In the present study, we investigated the 
predictive ability of ToxCast HTS assays for end points tested in EDSP T1S, and we tested the 
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hypothesis that if a chemical activates the estrogen or androgen receptor in vitro, estrogen-and 
androgen-related effects will occur in in vivo bioassays. Ideally, HTS tests should be highly 
reproducible and yield a minimal number of false-positive (specificity) and false-negative 
(sensitivity) chemicals. 
Previous studies have suggested the use of HTS assays for identifying endocrine disrupt-
ing potential. For example, the ReProTect project developed within the 6th European Framework 
Program tested 14 in vitro assays using 10 prototype compounds to determine feasibility for a 
reproductive screening program (Schenk et al. 2010). Those in vitro assays were grouped into 
three segments of the reproductive cycle: endocrine disruption, fertility, and embryonic 
development. The results of ReProTect showed, at least for the 10 prototype chemicals, that 
appropriate in vitro assay selection can effectively group compounds based on known reproduc-
tive toxicity (Schenk et al. 2010). 
HTS assays are useful for identifying chemical impacts on molecular initiating events in 
biological or toxicological pathways. Combinations of HTS assays measuring competitive ligand 
binding, reporter gene activation, and enzyme inhibition can be used to characterize chemical 
potential for endocrine disruption. These chemical characterizations can then be quantitatively 
evaluated by investigating associations with guideline EDSP T1S assay results. The aim of the 
present study was to use this data-driven approach to identify candidate MOAs for predictive 
modeling efforts, which subsequently will be used to prioritize chemicals for further endocrine-
related testing. 
 36
  
 
Methods 
Chemical Selection 
 In this study we used data from the ToxCast Phase I chemical library, containing data for 
309 unique chemical structures (U.S. EPA 2012e). Most of these chemicals are either current or 
former active ingredients in food-use pesticides that were designed to be bioactive, or they are 
industrial chemicals that are environmentally relevant. Details of the chemical library were 
reported by Judson et al. ( 2009). Data on an additional 23 reference chemicals were included 
that were tested in a separate study (Judson et al. 2010), 17 of which were not in the ToxCast 
Phase I library. CAS registry numbers (CASRN) for the ToxCast Phase 1 chemicals and the 
additional 17 chemicals are available online in Supplemental_File_1.csv (Rotroff et al. 2013). 
Guideline and Non-Guideline Endocrine Assays 
 Data from guideline endocrine-related in vitro and in vivo studies were extracted from 
EDSP Tier 1 validation reports from the U.S. EPA EDSP web site (U.S. EPA 2012a). Non-
guideline studies were obtained from open literature by querying PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) and Google Scholar (http://scholar.google.com/) using 
the following terms: (any chemical name or CASRN in the 309) AND (“in vitro” OR “in vivo”) 
AND (“estrogen” OR “androgen” OR “uterotrophic” OR “Hershberger” OR “steroidogenesis” 
OR “thyroid hormone”). The automated search found a wide variety of studies representing 
2,113 individual studies. The list of studies was manually curated to remove studies that did not 
contain data usable for the current analysis, leaving 248 unique studies (e.g., studies of mixtures 
without testing compounds individually, studies that mentioned the chemical but did not test it in 
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a bioassay, studies measuring bioaccumulation). Studies that identified their methods as 
following the Organisation for Economic Co-operation and Development (OECD) guidelines 
(Kanno et al. 2001, 2003; OECD 1999, 2001, 2003, 2007) or EDSP protocols were grouped 
together with EDSP T1S data for the guideline analysis. When available, PubMed identifiers 
(PMID) were used as unique annotations for each report. For the few instances when no PMID 
was available or for each EDSP T1S validation report, a unique identifying number was gen-
erated. The citation information for all documents used in the analysis is available online in 
Supplemental_File_2.txt (Rotroff et al. 2013). 
Guideline endocrine-related assays gathered from EDSP validation reports and OECD 
guideline studies were categorized according to whether they tested estrogen-, androgen-, 
steroidogenesis-, or thyroid-related MOAs (guideline-E, guideline-A, guideline-S, guideline-T, 
respectively). Additional information captured included study type (e.g., amphibian 
metamorphosis, reporter gene), assay type (e.g., serum levels, organ weight), species, strain, cell 
type, target, and whether or not it was an EDSP/OECD guideline study. Chemical potency [e.g., 
concentration at half-maximum activity (AC50), lowest effective concentration] for a given end 
point was captured as it was represented in the study report along with the maximum 
concentration/dose tested. In addition, agonist or antagonist responses were noted when appli-
cable. Data from guideline and non-guideline studies were dichotomized as either active if a 
response was observed, or inactive if no response was observed. If a study investigated multiple 
end points for a given endocrine MOA and produced at least one statistically significant end 
point, then that study–chemical–MOA combination was considered active. Activity/inactivity 
was determined based on the presence of a statistically significant response or was based on the 
study author’s conclusion. Data were further annotated as having a hit value of either 1 or 0 for 
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active and inactive, respectively. We combined all guideline and non-guideline literature studies 
so as to have a single hit value for each study–chemical–MOA combination. Data that were con-
flicting or otherwise unclear were included in the data table but annotated as such, and removed 
from analyses. The data obtained from guideline endocrine-related studies and other non-
guideline literature reports are available online Supplemental_File_3.csv (Rotroff et al. 2013). 
ToxCast In Vitro Assays 
 HTS competitive binding, enzyme inhibition, and reporter gene assays representing 
estrogen-, androgen-, steroidogenesis-, or thyroid-related end points (HTS-E, HTS-A, HTS-S, 
HTS-T, respectively) were selected as a subset of the > 500 HTS assays generated by the 
ToxCast program (ToxCastDB v.17; U.S. EPA, 2012e) [see Supplemental_File_1.csv (Rotroff et 
al. 2013)]. The details and a description of each assay are reported in Table 2.1. 
For chemicals that produced a statistically significant and concentration-dependent 
response in a given assay, the AC50 was recorded. The criteria for determining the activity of a 
compound are assay platform. The data were then dichotomized so that if an AC50 was present 
for a given chemical end point concentration, a 1 was reported; if no response was observed, a 0 
was reported. Chemicals tested in triplicate for quality control purposes were designated 1 or 0 
on a majority basis. Chemicals that were run in duplicate with at least one sample producing an 
AC50 were designated as a 1.  
Model Development 
We performed an iterative, balanced optimization analysis to determine the ability of 
ToxCast HTS assays to correctly classify the results of guideline endocrine-related assays while 
maintaining balance between sensitivity and specificity. The process for this analysis is 
illustrated in Figure 2.2. Because each HTS endocrine MOA may have multiple ToxCast HTS 
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assays, we used disjunctive logic employing varied weight-of-evidence thresholds to determine 
optimal predictive performance. This model tested variable thresholds for the HTS ToxCast 
assay results represented as unweighted binary data, while the guideline or non-guideline 
endocrine-related assay results remained static. Initially, the model began with a threshold 
criterion of one positive ToxCast HTS assay out of the total number of ToxCast HTS assays for a 
chemical to be considered to perturb a given MOA. Once calculated, the model was then re-run 
with increasing increments of one assay until all ToxCast HTS assays for a given endocrine 
MOA were required to be positive for a chemical to be considered to perturb the given MOA. As 
the threshold for a positive call was increased, a larger weight of evidence was required for a 
chemical to be considered a “hit” for perturbing the given endocrine MOA. An exception was 
made for guideline pubertal studies and the ToxCast NVS_NR_hAR assay. Guideline pubertal 
studies test for effects that can arise through multiple different endocrine-related pathways. For 
this reason, if a chemical was considered positive in the pubertal assay and the result conflicted 
with other guideline studies (e.g., receptor binding, reporter gene), the pubertal assay was not 
included in the weight of evidence. The ToxCast NVS_NR_hAR assay is a human androgen 
receptor binding assay in the LNCaP prostatic cell line. The androgen receptor in this cell line is 
known to bind to steroid hormones other than androgens (Veldscholte et al. 1992). For this 
reason, if a compound was negative in all other HTS-A assays, the result for the NVS_NR_hAR 
assay was not included in the weight-of-evidence. 
For a specific set of criteria across all overlapping chemicals, we calculated sensitivity, 
specificity, and balanced accuracy (BA) as measures of model performance (Figure 2.2B). The 
guideline analysis was performed comparing ToxCast HTS assays and guideline endocrine 
assays gathered from EDSP validation reports and OECD guideline studies. We also conducted a 
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separate non-guideline analysis comparing ToxCast HTS assays with assays from non-guideline 
studies. Many of the EDSP/OECD guideline studies and those reported in non-guideline litera-
ture used multiple studies/assays for each chemical–MOA combination. Because separate studies 
are not always in agreement relative to a chemical–MOA perturbation, the model was run using 
two scenarios: a) Any positive report for a chemical resulted in a positive call for the chemical–
MOA combination; or b) > 50% (threshold > 0.50) of guideline or non-guideline endocrine-
related studies or assays must report the chemical to be active for a given endocrine MOA. 
For each threshold criteria the number of true positives (TP), false positives (FP), true 
negatives (TN), and false negatives (FN) were calculated. A TP was any chemical determined to 
be positive in the ToxCast HTS assays and was also positive in guideline endocrine reports. A 
FP was positive in ToxCast but reported as negative in the guideline endocrine reports. If a 
chemical was determined to be negative in the ToxCast HTS assays and positive in the guideline 
endocrine reports, then it was recorded as a FN. Last, a TN was any chemical negative in the 
ToxCast HTS assays and negative in the guideline endocrine reports. At each threshold 
combination, all of the available chemicals were classified as TP, FP, TN, or FN and were used 
to calculate sensitivity, specificity, and BA as a measure of model performance. 
Statistical Analysis 
To identify statistically significant BA values, we performed a permutation test. The test 
randomized which ToxCast assays were associated with guideline endocrine studies or 
biomedical literature for each endocrine MOA in order to determine whether or not a randomly 
chosen set of assays from the > 500 ToxCast end points would likely produce a similar 
association. The BA calculation based on random assay associations was performed using the 
same number of ToxCast assays as the model and with the same threshold criteria. Assays were 
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permuted 10,000 times to build the random BA population distribution, and the percentile where 
the model BA fell among this distribution was calculated to provide a p-value. A p-value of < 
0.01 was considered statistically significant. The distributions developed from the permutation 
tests were used to define the confidence intervals in Figures 2.3 and 2.4. 
 
Results 
Data Collection 
 Data covering guideline endocrine-related in vitro and in vivo assays was extracted from 
documents used in EDSP Tier 1 validation or conducted according to OECD guidelines. We 
found a total of 40 studies covering 154 unique chemicals, resulting in a total of 1,246 captured 
end points. Table 2.2 shows the chemical overlap between the ToxCast chemical library and the 
chemicals captured from guideline and non-guideline studies. Twenty-one chemicals available 
from EDSP validation documents and other OECD guideline studies covering the guideline-E 
MOA overlapped with the ToxCast HTS-E assays. Thirteen chemicals overlapped in the 
corresponding guideline-A assays, 8 in the guideline-T assays, and 17 in the guideline-S assays. 
We extracted additional data used in a separate analysis from a total of 215 non-guideline studies 
[see Supplemental_File_3.csv available online (Rotroff et al. 2013)]. 
Model Results. 
 The results presented in Figure 2.3 demonstrate the predictive ability of ToxCast HTS-E 
and HTS-A assays relative to the corresponding endocrine MOA in the guideline endocrine-
related studies. Detailed results from the univariate model with guideline studies are available 
online in Supplemental_File_4.csv (Rotroff et al. 2013). 
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Comparison of HTS and guideline endocrine assays. For HTS-E end points, we obtained 
an optimal BA of 0.91 (p < 0.001) with a sensitivity of 0.89 and a specificity of 0.92, a threshold 
of two positives for ToxCast HTS-E assays, and > 50% for guideline-E studies (Figure 2.3). This 
means a minimum of two ToxCast HTS-E assays must report an AC50 value for a chemical to 
be considered positive, and > 50% of guideline-E assays must be reported as positive in the 
EDSP validation reports or OECD guideline studies. Overlapping HTS-E and HTS-A chemicals 
and corresponding performance in the HTS and guideline studies is provided in Tables 2.3 and 
2.4. Twenty-one guideline-E–related chemicals overlapped with ToxCast Phase I chemicals. One 
chemical, chlorpyrifos-methyl (CASRN 5598-13-0), was misclassified as a positive (FP) and one 
chemical, prochloraz (CASRN 67747-09-5), was misclassified as a negative (FN) by this set of 
ToxCast assays. If the goal was to optimize sensitivity, a threshold criteria of one ToxCast 
HTS-E assay and > 50% of guideline-E would produce a perfect sensitivity of 1, but specificity 
drops to 0.5 across this set of ToxCast HTS-E assays [see Supplemental_File_4.csv  available 
online (Rotroff et al. 2013)]. An additional analysis was conducted in which the threshold criteria 
for the guideline-E assays lowered from > 50% to any single positive report resulted in a positive 
call. This lowers the sensitivity from 0.89 to 0.5, and the overall BA drops to 0.75 (Figure 2.3). 
Figure 2.3 demonstrates the predictive ability of the ToxCast HTS-A assays and the 
guideline-A results. The optimal predictive ability of the ToxCast HTS-A assays was reached 
with a threshold of one HTS-A assay and a threshold > 50% for the guideline-A assays. This set 
of criteria produced a BA of 0.92 (p < 0.001), with a sensitivity of 0.83 and specificity of 1 
(Table 2.4). The results for HTS-S and HTS-T were not statistically significant among any of the 
analyses, with BAs of 0.56 (p > 0.01) and 0.50 (p > 0.01), respectively [see 
Supplemental_File_4.csv available online (Rotroff et al. 2013)]. 
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Comparison of HTS and uterotrophic and Hershberger assays. A separate analysis was 
conducted to determine the predictive capability of the ToxCast HTS-E assays to detect positive 
and negative chemicals reported in EDSP/OECD guideline uterotrophic assays (Figure 2.3). 18 
Eighteen chemicals were available for comparison, and the optimal thresholds for HTS-E 
produced a BA of 0.9 (p < 0.001), with a sensitivity and a specificity of 0.88 and 0.9, 
respectively. 
In addition, we determined the predictive ability of ToxCast HTS-A assays for 
EDSP/OECD guideline Hershberger results. Although, only six chemicals were available for 
comparison, the analysis resulted in a BA of 1 (p < 0.001), with a perfect measure of sensitivity 
and specificity with thresholds of one positive assay required for both HTS-A and EDSP/OECD 
guideline Hershberger reports (Figure 2.3). 
Comparison of HTS and non-guideline study assays. Predictive modeling results for non-
guideline studies in the biomedical literature are presented in Figure 2.4. All results from the 
analysis with non-guideline studies are available online in Supplemental_File_5.csv (Rotroff et 
al. 2013). The HTS-E MOA produced a maximum BA of 0.74 (p < 0.01), with at least one 
ToxCast assay being positive (ToxCast HTS-E threshold of 1) and a literature threshold of > 
50%. These criteria produced a sensitivity of 0.75 and a specificity of 0.72. Because of the wide 
range of test conditions, assay technologies, and species present in the open-literature, sensitivity 
was lower than in the guideline studies. This is apparent because of the model optimization that 
occurred with only one HTS-E assay required for a positive classification, compared with 
optimizing at two assays in the guideline analysis. We observed an overall concordance of 0.7 
between the guideline-E assay results and the estrogen-related literature results given the stated 
thresholds (data not shown). 
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The optimal BA reached 0.65 (p > 0.01) with the ToxCast HTS-A assays threshold of 1 
and and androgen-related literature threshold > 50%. At these thresholds, sensitivity was low 
(0.3) but specificity was 1 (Figure 2.4). There was a concordance between chemical 
classifications for guideline-A reports and non-guideline reports of 0.77 at the reported 
thresholds of > 50% (data not shown). 
 
Discussion 
 The results of this study demonstrate that ToxCast in vitro assays perform adequately to 
prioritize chemicals for further EDSP T1S for estrogen and androgen activity, and these HTS 
assays are predictive of the likelihood of a positive or negative finding in more resource-
intensive assays. Additional HTS assays will be needed to predict steroidogenic and thyroid 
activity of chemicals. Methods for prioritizing chemicals based on a broad range of ToxCast 
HTS assays, in combination with physical–chemical properties, have been previously developed 
(Reif et al. 2010). Other efforts are also under way to develop more sophisticated, pathway-based 
predictive models that would be more suitable for supporting regulatory decision making. The 
present study demonstrates the MOA for which these models would be expected to succeed, and 
for which areas need additional technologies before a sufficient screening tool would be 
expected to be successful. This information can now be used for more focused follow-up efforts 
to identify endocrine-related MOAs for prioritization. 
The HTS-E and HTS-A assays demonstrate a high degree of association with the 
guideline-E and guideline-A assays. The two types of misclassifications, FP and FN, are 
important because they highlight shortcomings in the model or further specify the domain of 
applicability. FPs are compounds predicted to be active but that were not active in this analysis 
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based on the threshold of EDSP/OECD reports or literature data. These are significant because a 
FP could lead to unnecessary testing in more resource intensive assays, and FNs are of concern 
because they represent potentially active chemicals that would have gone undetected. 
The HTS-E model correctly classified 90% of chemicals, and only 2 of 21 chemicals 
were misclassified as FP or FN. Chlorpyrifos-methyl was an FP, meaning that it was predicted to 
be estrogenic by ToxCast HTS-E assays but was not positive in the only guideline-E report, 
which was a uterotrophic study by Kang et al. (2004) (Table 2.3). This same chemical was 
reported to be inactive in all of the extracted non-guideline-E literature data (active in 0 of 4 
available assays). Chlorpyrifos-methyl was inactive in all ToxCast HTS-E assays except for the 
Attagene ERα TRANS and CIS reporter gene assays, which resulted in the subsequent positive 
call. 
Non-guideline estrogen-related literature for prochloraz reported observations of ERα 
antagonism in some reporter gene and proliferation assays (Bonefeld-Jorgensen et al. 2005; 
Kjærstad et al. 2010), but other studies did not observe activity in reporter gene assays (Kojima 
et al. 2004; Lemaire et al. 2006; Petit et al. 1997; Andersen et al. 2002) or proliferation assays 
(Andersen et al. 2002; Vinggaard et al. 1999) [see Supplemental_File_3.csv  available online 
(Rotroff et al. 2013)]. Prochloraz was a FN in this analysis as because it was active in the NCGC 
ERα NCGC_ERalpha_Antagonist assay but negative in all other ToxCast HTS-E binding and 
reporter gene assays [see Supplemental_File_1.csv available online (Rotroff et al. 2013)]. 
Prochloraz tested positive in the only guideline-E assay available (Table 2.3). This EDSP/OECD 
fathead minnow assay showed altered fecundity, vitellogenin, and oocyte atresia after prochloraz 
treatment (U.S. EPA 2007). Prochloraz is known to disrupt steroidogenesis through inhibition of 
CYP (cytochrome P450) 17 hydroxylase and aromatase, preventing the critical conversion of 
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progesterone to 17α-hydroxyprogesterone and testosterone to 17β-estradiol, respectively 
(Blystone et al. 2007; Sanderson et al. 2002). The fathead minnow assay likely detected this 
non–receptor-mediated mechanism of estrogen disruption, and this mechanism of action would 
not have been expected to be detected in the current set of ToxCast HTS-E assays. Prochloraz 
was the only compound misclassified in the HTS-A analysis, and the effects observed in the 
reproductive study in male fish are likely a result of the same steroidogenic perturbations. 
Prochloraz was correctly identified by the ToxCast aromatase enzyme inhibition assay, which 
was grouped with the HTS-S–related MOA. 
Although a limited number of chemicals was available for comparison, we found a strong 
association between the ToxCast HTS-E and HTS-A assays with EDSP/OECD guideline 
uterotrophic and Hershberger studies. Eighteen chemicals were available for comparison 
between ToxCast HTS-E and guideline uterotrophic assays and only two were misclassified 
(Table 2.3). Six chemicals were available for analysis between ToxCast HTS-A assays and 
Hershberger responses, and all of these chemicals were classified correctly for a perfect BA of 1 
(Table 2.4). 
There are several explanations for why a chemical may be misclassified by the ToxCast 
HTS models. In some scenarios a chemical may not have been tested at concentrations high 
enough to exhibit a response in ToxCast assays. Inconsistencies could also result from species, 
tissue, or cell-type differences between the ToxCast and guideline studies. Most of the ToxCast 
assays use human cell lines or reporter constructs, and some areas of misclassification may result 
from species differences between these assays and the rodent bioassays. Comparisons of 
available species between guideline and non-guideline studies are available in Table 2.5. 
Interspecies differences should be taken into consideration because they may be quite 
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substantial. For example, studies have highlighted not only the importance of tissue and cell 
distribution and context within an organism for both ER and AR (Kolasa et al. 2003; Zhou et al. 
2002) but also the presence of ERα and ERβ splice variants (Saunders et al. 2002). Most in vitro 
assays are limited in their metabolic capabilities, so chemicals that require metabolic activation 
in order to be active may not be detected. However, methoxychlor and vinclozolin, which 
become more active with metabolism, were both detected in the HTS-E (Table 2.3) and HTS-A 
(Table 2.4) assays. Furthermore, in vivo assays may detect chemicals that perturb endocrine-
related end points elicited via toxicity in other organs, such as the liver (Leffert and Alexander 
1976; Masuyama et al. 2000; Xie et al. 2003). The assays selected for the present study comprise 
only a small portion of the overall endocrine pathway domain. Alterations in neuroendocrine or 
other pathways, as well as some feedback mechanisms, could be affected by a compound and 
would not be detected by these assays. The methods we used to classify compounds may result 
in different conclusions than those obtained by the EDSP (U.S. EPA 2011b). Despite these 
limitations, evidence from the present study indicates that very few chemicals that are active in 
EDSP T1S go undetected by ToxCast HTS-E and HTS-A assays. Most of the misclassifications 
appear to be from downstream estrogenic and androgenic effects caused by alterations of 
upstream steroidogenic enzymes. Most of the active guideline-E and guideline-A chemicals in 
this data set appear to operate through receptor-mediated pathways and are detectable in vitro. 
The non-guideline literature analysis demonstrated that ToxCast HTS assays are also 
predictive of a broader range of endocrine-related assays. As expected, we observed a loss of 
accuracy in predicting the non-guideline literature analysis compared with the EDSP/OECD 
guideline studies because the non-guideline literature studies used a wide variety of species, 
assay protocols, and technologies. An additional factor that led to the loss of sensitivity in the 
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HTS-A non-guideline analysis was the imbalance of positive to negative reports. The guideline 
study had 6 positives of 13 total chemicals (46%) at > 50% threshold, and the non-guideline 
reports had 47 positives of 59 total chemicals (80%) at the same threshold. The sensitivity would 
be expected to improve with a more balanced data set. 
 This analysis shows that there is a clear need to develop HTS assays capable of detecting 
steroidogenesis and thyroid disrupting compounds. The current HTS-S related assay within 
ToxCast is limited to a single cell-free aromatase enzyme activity assay. Aromatase is a key 
enzyme in the biosynthesis of estrogens from androgens (Schuurmans et al. 1991; Stoker et al. 
2000a). However, in addition to aromatase inhibition, other mechanisms of steroidogenesis may 
be impacted by environmental chemicals that are not tested in our current HTS battery (Stoker et 
al. 2000a, 2000b). Additional assay technologies that may provide a more comprehensive set of 
steroidogenesis end points are currently being assessed. 
The ToxCast HTS-T assays used in our analysis are composed of thyroid hormone 
receptor binding and reporter gene assays. A limited number of chemicals was available for 
comparison between the HTS-T assays and the guideline studies. The inability of the ToxCast 
HTS-T assay results to associate with compounds thought to disrupt thyroid homeostasis in 
EDSP/OECD guideline studies suggests that most of these compounds are not acting through 
thyroid hormone receptor-mediated mechanisms (Paul et al. 2010; Zorrilla et al. 2009)(Paul et 
al., 2010; Zorrilla et al., 2009). Thyroid hormone homeostasis has been shown to be altered 
through enhanced or suppressed clearance of thyroid hormone by metabolic enzymes (Saghir et 
al. 2008; Zorrilla et al. 2009). ToxCast contains HTS assays that measure nuclear receptor 
activation and metabolic enzyme activity, which could be relevant for thyroid hormone 
metabolism. However, many chemicals that were active in these in vitro ToxCast assays were 
 49
not associated with adverse outcomes in the in vivo literature we reviewed, and the subsequent 
lack of specificity for thyroid-active chemicals led to their exclusion from this analysis (data not 
shown). 
From these findings, we conclude that most chemicals chosen to validate EDSP T1S assays alter 
estrogen- and/or androgen-related end points through nuclear receptor-mediated mechanisms and 
are capable of being efficiently detected by the ToxCast HTS assays. For the purpose of 
prioritization, it is important to establish sufficient confidence that the assays being utilized are 
specific and sensitive so that chemicals prioritized for EDSP T1S include those most likely to be 
active. Although further efforts are needed to improve detection of steroidogenic and thyroid-
disrupting chemicals with in vitro test systems, our results indicate that ToxCast endocrine 
assays are highly predictive of chemicals with estrogenic and androgenic receptor-based 
endocrine MOAs, and that their use in predictive models for endocrine testing would allow 
efficient prioritizing of chemicals for further testing. 
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Tables 
Table 2.1. Summary of Endocrine Related HTS Assays  
 
ToxCast Assay 
Assigned    
MOA Species Assay Target Assay Technology 
Unique 
Chemical
s Tested 
EDSP/OECD 
Overlapping 
Chemicals 
Overlapping 
active chemicals 
in ToxCast 
ATG_AR_TRANS HTS-A Human Androgen Receptor-Agonist Multiplexed reporter gene assay 309a 13 0 
NCGC_AR_Agonist HTS-A Human Androgen Receptor-Agonist GAL4 BLAM Reporter gene assay 309 13 0 
NCGC_AR_Antagonist HTS-A Human Androgen Receptor-Antagonist GAL4 BLAM Reporter gene assay 309 13 5 
NVS_NR_hAR HTS-A Human Androgen Receptor Competitive Binding 309 13 6 
NVS_NR_rAR HTS-A Rat Androgen Receptor Competitive Binding 309 13 1 
ATG_ERa_TRANS HTS-E Human Estrogen Receptor-α Multiplexed reporter gene assay 326b 21 12 
ATG_ERE_CIS HTS-E Human Estrogen Receptor Response 
Element Multiplexed reporter gene assay 326
b
 21 11 
ATG_ERRa_TRANS HTS-E Human Estrogen Related Receptor-α Multiplexed reporter gene assay 326b 21 0 
ATG_ERRg_TRANS HTS-E Human Estrogen Related Receptor-γ Multiplexed reporter gene assay 326b 21 0 
NCGC_ERalpha_Agonist HTS-E Human Estrogen Receptor-α-Agonist GAL4 BLAM Reporter gene assay 326b 21 7 
NCGC_ERalpha_Antagonist HTS-E Human Estrogen Receptor-α-Antagonist GAL4 BLAM Reporter gene assay 309 15 4 
NVS_NR_bER HTS-E Bovine Estrogen Receptor Competitive Binding 316b 17 1 
NVS_NR_hER HTS-E Human Estrogen Receptor Competitive Binding 326b 21 4 
NVS_NR_mERa HTS-E Mouse Estrogen Receptor-α Competitive Binding 316b 17 1 
NVS_ADME_hCYP19A1 HTS-S Human Aromatase Enzyme Inhibition 309 17 1 
NCGC_TRbeta_Agonist HTS-T Human Thyroid Hormone Receptor-β-Agonist GAL4 BLAM Reporter gene assay 309 8 0 
NCGC_TRbeta_Antagonist HTS-T Human Thyroid Hormone Receptor-β-Antagonist GAL4 BLAM Reporter gene assay 309 8 0 
NVS_NR_hTRa HTS-T Human Thyroid Hormone Receptor-β-Antagonist Receptor Activation 309 8 0 
a  Additional reference compounds from Judson et al. (2010) were run but not included because this is the only androgen-related HTS assay that tested these chemicals; b  
Includes additional reference compounds from Judson et al. 2010 
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Table 2.2. Summary of Endocrine Literature Survey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endocrine Modes 
of Action 
No. of 
Documents 
No. of Data 
Points 
No. of Unique 
Chemicals from 
Literature Survey  
No.  of Chemicals 
Overlapping with 
ToxCast 
Estrogenicity 18 (108) 410 (979)  104 (158) 21 (143) 
Androgenicity  22 (54) 571 (301) 60 (73) 13 (59) 
Steroidogenesis 10 (32) 123 (251) 44 (61) 17 (55) 
Thyroid  7 (48) 142 (190) 27 (57) 8 (47) 
ALL 40 (215) 1246 (1721) 154 (182) 35 (157) 
* Values represent guideline (non-guideline) 
studies. 
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Table 2.3. Chemical Results from Overlapping HTS-E and Guideline Reports  
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1912-24-9 Atrazine E 2 >50% 0.91 0.89 0.92 0 0 0 0 0 0 0 0 0 0 0 0/1 NA 1/0 0/1 1/0
17804-35-2 Benomyl E 2 >50% 0.91 0.89 0.92 0 0 0 0 0 0 0 0 0 0 0 0/1 NA NA 0/1 1/1
80-05-7 Bisphenol A E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 1 1 1 1 1 1/0 NA 0/1 NA 8/1
2425-06-1 Captafol E 2 >50% 0.91 0.89 0.92 0 0 0 0 0 0 0 0 0 0 0 1/0 NA NA 0/1 0/1
5598-13-0 Chlorpyrifos-methyl E 2 >50% 0.91 0.89 0.92 1 0 1 1 0 0 0 0 0 0 0 NA NA NA NA 0/1
84-74-2 Dibutyl phthalate E 2 >50% 0.91 0.89 0.92 0 0 1 0 0 0 0 0 0 0 0 NA NA NA NA 0/3
117-81-7 Diethylhexyl phthalate E 2 >50% 0.91 0.89 0.92 0 0 0 0 0 0 0 0 0 0 0 1/0 NA NA 0/1 0/1
66230-04-4 Esfenvalerate E 2 >50% 0.91 0.89 0.92 0 0 1 0 0 0 0 0 0 0 0 NA NA NA NA 0/1
60168-88-9 Fenarimol E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 1 1 0 0 0 NA NA 1/0 NA NA
72-43-5 Methoxychlor E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 1 1 0 0 0 NA NA 1/0 NA 7/0
40487-42-1 Pendimethalin E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 0 0 0 0 0 NA NA NA NA 1/0
52645-53-1 Permethrin E 2 >50% 0.91 0.89 0.92 0 0 1 0 0 0 0 0 0 0 0 NA NA NA NA 0/1
67747-09-5 Prochloraz E 2 >50% 0.91 0.89 0.92 0 1 0 0 0 0 0 1 0 0 0 NA 1/0 NA NA NA
3380-34-5 Triclosan E 2 >50% 0.91 0.89 0.92 0 0 0 0 0 0 0 0 0 0 0 NA NA 1/0 NA 0/1
50471-44-8 Vinclozolin E 2 >50% 0.91 0.89 0.92 0 0 0 1 0 0 0 0 0 0 0 NA 0/1 NA NA NA
104-40-5 4 Nonylphenol E 2 >50% 0.91 0.89 0.92 0 0 0 1 0 0 0 NA 0 0 0 1/0 NA NA NA NA
140-66-9 4-(tert-octyl)Phenol E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 1 NA NA 1 NA NA 1/0 NA NA 2/0
521-18-6 5a-androstan-17b-ol-3-one E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 1 NA NA 0 NA NA NA NA NA 1/0
50-28-2 b-estradiol E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 1 NA NA 1 NA 1/0 NA NA NA 3/0
13311-84-7 Flutamide E 2 >50% 0.91 0.89 0.92 0 0 0 0 0 0 0 NA 0 0 0 0/1 NA NA 0/1 0/1
446-72-0 Genistein E 2 >50% 0.91 0.89 0.92 1 1 1 1 0 0 1 NA NA 1 NA 1/0 NA NA NA 5/0
HTS Assays Guideline Chemical Information Model Parameters and Results
Chemicals Results Overlapping HTS-E and Guideline-E
a
 1 indicates positive result, 0 indicates negative result         
b
 (# of positive reports/# number of negative reports)           
c
 Conflicting pubertal studies were ignored (See methods)           
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Table 2.4. Chemical Results from Overlapping HTS-A and Guideline Reports 
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1912-24-9 Atrazine A 1 >50% 0.92 0.83 1 0 0 0 0 0 0 0 NA 0/1 NA NA 2/0
80-05-7 Bisphenol A A 1 >50% 0.92 0.83 1 1 1 0 0 1 1 0 NA 1/0 NA NA NA
84-74-2 Dibutyl phthalate A 1 >50% 0.92 0.83 1 0 0 0 0 0 0 0 0/1 NA NA NA 1/0
117-81-7 Diethylhexyl phthalate A 1 >50% 0.92 0.83 1 0 0 0 0 0 0 0 NA 0/1 NA NA NA
66230-04-4 Esfenvalerate A 1 >50% 0.92 0.83 1 0 0 0 0 0 0 0 NA NA NA 0/1 NA
122-14-5 Fenitrothion A 1 >50% 0.92 0.83 1 1 1 0 0 1 1 1 NA NA NA 1/0 NA
330-55-2 Linuron A 1 >50% 0.92 0.83 1 1 1 0 0 1 1 0 1/0 1/0 NA 9/0 1/0
72-43-5 Methoxychlor A 1 >50% 0.92 0.83 1 1 1 0 0 1 0 0 NA 1/0 NA NA 0/1
52645-53-1 Permethrin A 1 >50% 0.92 0.83 1 0 0 0 0 0 0 0 NA NA NA 0/2 NA
67747-09-5 Prochloraz A 1 >50% 0.92 0.83 1 0 1 0 0 0 1 0 NA NA 1/0 NA NA
7696-12-0 Tetramethrin A 1 >50% 0.92 0.83 1 0 0 0 0 0 0 0 NA NA NA 0/1 NA
3380-34-5 Triclosan A 1 >50% 0.92 0.83 1 0 0 0 0 0 1 0 NA NA NA NA 0/1
50471-44-8 Vinclozolin A 1 >50% 0.92 0.83 1 1 1 0 0 1 1 0 1/0 1/0 1/0 4/0 1/0
a
 1 indicates positive result, 0 indicates negative result                                                              
b
 (# of positive reports/# number of negative reports)                                                                 
c
 Conflicting pubertal studies were ignored (See methods)                                                        
d
 Additional positives from other assays required for positive call (See methods)
Chemicals Results Overlapping HTS-A and Guideline-A
Chemical Information Model Paramters and Results Guideline HTS Assays
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Table 2.5. Test Species in Guideline and Non-Guideline In Vitro and In Vivo Studies 
Organism Non-Guideline-E Guideline-E Non-Guideline-A Guideline-A
Human
Bovine
Atlantic Croaker
Kelp Bass
Rat 
Fathead Minnow
Mouse
Rat
Rainbow Trout
Rabbit
Chicken
Green Anole
Channel Catfish
Zebrafish
Xenopus
Caiman
Whiptail Lizard
Largemouth Bass
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Figures 
 
Figure 2.1. Overlap between EDSP T1S assays and ToxCast phase I assays by endocrine MOAs. 
Abbreviations: A, androgen; E, endocrine; NA, not applicable; T, thyroid. Colors indicate the 
type of endocrine MOA data. 
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Figure 2.2. Illustration of the balanced optimization model used to analyze predictive capacity of 
endocrine-related ToxCast assays. Multiple assays and study reports were available for each 
chemical–MOA combination. (A) Snapshot of a step in this modeling/optimization process, in 
which chemical X is positive in three of five HTS assays and two of three guideline reports. In 
this example, the dynamic HTS threshold is at least two positive assays and the guideline 
threshold is at least 50% positive reports, so chemical X is considered a true positive (TP). With 
less than two positive assays, chemical X would be a false negative (FN); < 50% positive reports 
would produce a false positive (FP); and if both were negative according to this criteria, then 
chemical X would be a true negative (TN). (B) Method for tabulating results for all chemicals 
(e.g., chemical X would be counted in the TP portion of the contingency table) to arrive at an 
estimate of balanced accuracy for each of the threshold parameters.  
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Figure 2.3. Forest plot illustrating the performance —as measured by sensitivity, specificity, and BA—of ToxCast endocrine-related 
assays for predicting outcomes captured in EDSP/OECD guideline studies. Symbols represent the optimal BA obtained across all 
threshold combinations and the corresponding sensitivity and specificity at the same threshold. Gray boxes indicate 95% confidence 
intervals around permuted BA distributions. Analyses designated “All” include all available assays for the stated endocrine MOA. A 
value of > 50% “required guideline positives” indicates that > 50% of the studies had to report a positive result for a chemical to be 
considered a positive in the analysis. If the “required guideline positives” value is designated 1, then any study reporting a positive 
resulted in the chemical being considered positive in the analysis. A separate analysis compared only uterotrophic and Hershberger 
analyses (right). Statistical significance is reported as * p < 0. 1, ** p < 0.05, *** p < 0.001 by Fisher’s exact test. 
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Figure 2.4 Forest plot illustrating the performance—as measured by sensitivity, specificity, and BA—of ToxCast endocrine-related 
assays for predicting outcomes captured in non-guideline endocrine studies. Symbols represent the optimal BA obtained across all 
threshold combinations and the corresponding sensitivity and specificity at the same threshold. Gray boxes indicate 95% confidence 
intervals around permuted BA distributions. A value of > 50% “required non-guideline positives” indicates that > 50% of the studies 
had to report a positive result for a chemical to be considered a positive in the analysis. If the “required non-guideline positives” 
column value is designated 1, then any study reporting a positive resulted in the chemical being considered positive in the analysis. 
Statistical significance is reported as * p < 0.1, ** p < 0.05, *** p < 0.001 by Fisher’s exact test.  
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CHAPTER 3 
REAL-TIME GROWTH KINETICS MEASURING HORMONE MIMICRY FOR 1816 
UNIQUE TOXCAST CHEMICALS IN T-47D HUMAN DUCTAL CARCINOMA CELLS 
 
 
Introduction 
Many xenobiotic chemicals are able to interact with molecular targets in the endocrine 
system, making screening for potential endocrine disrupting compounds (EDCs) an important 
issue (Soto and Sonnenschein 2010; Tilghman et al. 2010). One possible effect of endocrine 
disrupting chemicals is perturbation of cell growth through pathways linked to cell cycle 
regulation (Davis et al. 1997; Doisneau-Sixou et al. 2003). Activation of the estrogen receptor 
(ER) signaling pathway, for example, is one possible mechanism that underlies cell proliferation 
in hormonally-sensitive tissues such as mammary and endometrial tissue (Doisneau-Sixou et al. 
2003; Shiozawa et al. 2004). The ER signaling pathway is involved in a number of complex 
signaling cascades that can influence many genes, e.g., up to 26% of the transcriptome in MCF-7 
human mammary ductal carcinoma cells (Hah et al. 2011). Furthermore, the role of steroid 
hormones in the regulation of some mammary tumors has been well established and has 
motivated the development of estrogen pathway-based chemotherapeutics (Crowder et al. 2009; 
Jordan and Morrow 1999; Oh et al. 2006; Vogel et al. 2006).  
The EPA formed the Endocrine Disruptor Screening Program (EDSP) in 1996, in 
response to The Federal Food, Drug, and Cosmetic Act (FFDCA), as amended by the Food 
Quality Protection Act (FQPA), to test substances for their potential to mimic the effect 
produced by a naturally occurring estrogen, or other such endocrine effects 
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(www.epa.gov/endo/). EDSP is a tiered program requiring chemical manufacturers to submit or 
generate data for regulatory decision making. The Tier 1 screening battery (T1S) consists of both 
in vitro and in vivo assays to test chemicals for their potential for estrogen, androgen, thyroid or 
steroidogenesis modes-of-action. The Tier 2 assay battery has not yet been determined, but will 
consist of more complex in vivo tests. The initial list of 67 chemicals for EDSP testing was 
finalized in 2009 and has yet to complete the T1S. There are thousands of chemicals subject to 
the T1S, and it is estimated that the T1S will cost ~$1 million per chemical (U.S. EPA 2011a, 
2011b).  
Due to the amount of resources required to meet the current test guidelines, the EPA 
launched the EDSP21 project, which is evaluating a new strategy using computational or in 
silico models, and molecular-based, in vitro assays to prioritize and eventually replace the more 
resource-intensive T1S assays (U.S. EPA 2011a). Previous studies have demonstrated that in 
vitro assay data can be used to accurately classify compounds relative to in vivo tests for certain 
modes of action for endocrine disruption (Rotroff et al. 2013; Schenk et al. 2010). Many of the 
assays under consideration for EDSP21 testing come from The U.S. EPA’s ToxCastTM program 
and the interagency Tox21TM program. ToxCast and Tox21 are designed to use high-throughput 
in vitro and in silico technologies to prioritize large numbers of chemicals for in vivo regulatory 
tests. In conjunction with prioritization, the goals of ToxCast are to guide targeted testing 
strategies and to build predictive models, which may eventually replace more costly, low-
throughput assays in a variety of applications beyond prioritizing chemicals in EDSP.    
This study analyzes a ToxCast assay that monitors cell growth kinetics in the estrogen 
responsive, human mammary ductal carcinoma cell line T-47D. An inventory of 1816 unique 
environmental chemicals was tested in the assay. These include a set of positive and negative 
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reference chemicals for ER activity.  This cell line expresses ERα and also contains androgen, 
glucocorticoid, and progesterone receptors (Keydar et al. 1979). Cell growth kinetics were 
assessed using real-time cell analysis (RTCA) on the xCELLigence system, which offers a more 
comprehensive evaluation of cellular growth kinetics compared to traditional in vitro viability 
and proliferation assays. The assay uses electronic microsensors located at the bottom of the cell 
culture well to detect changes in cell number, morphology and adhesion through electrical 
impedance measurement at the electrode-solution interface (Figure 3.1). Here, we compare the 
results of this cell-impedance assay with other ER related assays in order to better understand the 
role of xenobiotics in ER mediated cell-level activity and further characterize the ability of in 
vitro HTS assays to detect these interactions 
 
Methods 
Chemical Selection  
 This study was conducted using data from three ToxCast chemical libraries and reference 
compounds totaling 1,816 unique chemicals. This inventory includes 293 unique chemical 
structures from the Phase Iv2 ToxCast chemical library, the majority of which are active 
ingredients of current or former food-use pesticides, or industrial chemicals of environmental 
relevance (Judson et al. 2009). An additional 676 unique chemical structures were from the 
ToxCast Phase II chemical library. The remaining 880 unique chemical structures were from the 
ToxCast E1K chemical library. Individual chemical library information can be found at 
http://www.epa.gov/ncct/toxcast/chemicals.html. All chemicals were shipped as 20mM stock 
solutions in DMSO. 
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During screening, 2 M MG132 (Tocris) was used as a positive control for cytotoxicity, 
200 and 500 pM 17-estradiol (Tocris) (E2) was used as a positive control for estrogen 
response. To characterize the specificity of the assay, progesterone (Sigma), dexamethasone 
(Sigma), aldosterone (Sigma) and EGF (Life Technologies) were used as reference compounds 
for response to progesterone receptor, glucocorticoid receptor, mineralcorticoid receptor and 
EGF receptor pathways, respectively. 
Experimental Procedures. 
 The xCELLigence system Multi-E-Plate stations were used to measure the time-
dependent response to chemicals described above by RTCA. Each compound was tested in an 
eight-point, 1:4 serial dilution series starting at a maximum final concentration of 100 M. A 
maximum starting concentration of 0.5% DMSO was present in the 100 M chemical samples 
and was diluted along with the test article dilution series. The screen was performed in biological 
duplicate using two separate, 96-well, E-Plates 96TM for each dilution series (n=2). Positive 
controls (MG132 and E2) and a negative control (assay media) were tested in quadruplicate on 
each testing plate. 0.5% and 0.125% DMSO were tested in duplicates in each plate to serve as 
solvent controls for the 2 highest concentrations of testing compounds: 100 M and 25 M. 
Reference compounds were tested with 8 concentrations with 1:5 serial dilutions. All screening 
was carried out by ACEA Biosciences, Inc. (San Diego, CA).  
T-47D cells purchased from ATCC were maintained in RPMI1640 media supplemented 
with 10% characterized fetal bovine serum (FBS). Before screening, T-47D cells were pre-
conditioned in assay medium: Phenol Red-free RPMI1640 supplemented with 10% charcoal-
stripped FBS. Cells were then detached and seeded in E-Plates 96 in assay medium. After 
overnight monitoring of growth once every hour, compounds were added to T-47D cells and 
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remained in the medium until the end of the experiment. Cellular responses were then recorded 
once every 5 min for the first 5 hours, and once every hour for an additional 100 hours.  
Data Processing 
Raw data were collected in the form of Cell Index (CI) for each of the time points before 
and after compound addition. Data were collated into *.csv files and converted to Normalized 
Cell Index (NCI) according to the following equation: 
 =

	
,  = 1,2,3, …, 
 where, CI(Tk) is the cell index at Tk, the last time point before compound addition, CI(Ti) is the 
cell index at Ti, the i-th measured time point, N is the number of total measured time points. 
Wells flagged for technical issues such as contamination or electronic failure were removed from 
analysis and substituted with the average of the duplicate chemical’s time points before and after 
the missing value. Data were then grouped by chemical and a simple moving average (SMA) 
was used to smooth the data in order to combine replicates for time course analysis: 
SMAt=
t-6 +t-5…+t+6
13  
where, SMAt is the simple moving average at time t, NCIt is the NCI at time t.  
17β-estradiol (E2) was run in quadruplicate on each plate, and the maximum average E2 
response on each plate was used as a positive control for all the test chemicals on that plate. 
Vehicle control (0.5% DMSO) wells were run in duplicate on each plate and the maximum 
average NCI was used as a negative control for all the test chemicals on that plate. If a chemical 
sample was run on two different plates, then the maximum NCI values for the positive and 
negative controls were averaged. All smoothed NCI values for the treatment chemicals were then 
converted to a percentage of the positive control value.  
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For cell loss, the NCI value at the time of compound administration was considered to 
represent complete (100%) viability. MG132 (2µM), a proteasome inhibitor and known 
cytotoxic agent, was used as the positive control for cell loss, and was tested in quadruplicate on 
each plate. The minimum average response on each plate was used as a positive control for cell 
loss for all the test chemicals on the corresponding plate. If a chemical sample was run on two 
different plates, then the minimum NCI values for MG132 were averaged. If an NCI value for 
MG132 fell below zero, the response was considered to be below the limit of detection, and was 
replaced with the minimum value greater than zero across all plates. All smoothened NCI values 
were then converted to a percentage of positive control, which was considered to represent no 
(0%) viability. 
Concentration Response Curves 
All concentration-response curves were fit using non-linear least squares regression in the 
open-source statistical software, R and the sfsmisc package (Maechler 2011; R Development 
Core Team 2011). For the cell growth analysis, cytotoxicity was ascribed to a particular 
chemical-concentration level when the response fell below 15% of the next lower test 
concentration. This concentration and all higher concentrations were flagged and excluded from 
the concentration response data prior to curve fitting. If a minimum of four responses remained 
after cytotoxicity filtering, then concentration response curves were fit for each time-point using 
the Hill-equation: 
 =  −  − 
1 +  50
 
where, Y is the response variable (% E2), T is the upper asymptote, B is the lower asymptote, X 
is the concentration, AC50 is equal to the concentration at which 50% of activity (response) 
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occurs, and W is the Hill-slope coefficient. The Hill-slope coefficient was constrained between 1 
and 8. The minimum value of Y produced was recorded as the minimum efficacy (EMIN), and the 
maximum value of Y produced was recorded as the maximum efficacy (EMAX). If the EMAX 
reached 25% of the window between the maximum growth attained by the negative control 
(0.5% DMSO) and the maximum growth of the positive control (200 pM E2 for Phase II 
chemicals, and 500 pM E2 for PhaseIv2 and E1K chemicals), then the chemical was assessed as 
‘active’ for T-47D cell growth. To ensure the quality of the controls, the ratio of active chemicals 
to the dynamic range of the negative and positive controls was calculated for each plate. Plates 
that were 3 standard deviations from the mean were substituted with the average negative and 
positive control values across all plates. This helped prevent false positives due to controls with a 
low dynamic range. After substituting with the average controls, the concentration responses for 
these curves were re-fit. If the EMIN for a chemical was greater than the threshold for activity 
(25%), then the chemical’s AC50 was set to the minimum concentration. A final manual curation 
was performed where active and inactive calls could be adjusted if the systematic curve fitting 
did not accurately reflect the data. This step was performed for all 80 h concentration response 
curves. An example of how the growth profiles translate into concentration response curves can 
be seen in Figure 3.2. 
A separate but similar approach was taken to assess cell loss. Concentration-response 
curves were fit for each time-point using the same Hill equation as the growth curves, but 
replaced with a negative Hill-slope coefficient. B was constrained to 0 (100% MG132), and the 
minimum value of Y produced was recorded as the EMIN. If the EMIN value dropped an arbitrary 
25% below the starting value of 100%, then the chemical was considered active by cell loss. 
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Replicate Concordance.  
All active and inactive chemicals at 80 h after compound administration that had at least 
two blinded duplicates across all three chemical libraries were used to assess replicate 
concordance. If a chemical produced either all active or inactive responses across available 
replicates, then that chemical was given a concordance value of 1. If a chemical produced 50% 
active responses, then that chemical was given a concordance value of 0. For all other 
combinations the concordance value was based on the number of active responses divided by the 
total number of replicates. This analysis was performed separately for cell growth and cell loss. 
ER Assay Comparison.  
Data on ToxCast Phase I and Phase II, totaling to 957 unique chemicals, from ER 
transactivation assays and ER binding were compared to the results from the cell growth analysis 
at 80 h. For the transactivation assay, all chemicals were tested in 8-point concentration-response 
format using 3-fold serial dilutions from a top concentration of 100µM (Phase I) or 200µM 
(Phase II) in Attagene Inc.’s cellular biosensor system (Factorial™). This system combines 
libraries of cis- and trans-regulated transcription factor reporter constructs with a highly 
homogeneous method of detection, enabling simultaneous evaluation of multiplexed 
transcription factor activities. The ERα assay endpoint from the TRANS system 
(ATG_ERa_TRANS) and the corresponding estrogen receptor response element from the CIS 
system (ATG_ERE_CIS) comprised the two ER transactivation assays used in all subsequent 
assay comparisons (Martin et al. 2010; Romanov et al. 2008). The human ER binding assay 
(hER) (Caliper, a PerkinElmer company, Hanover, MD) assessed whether the test compound 
could potentially interrupt estradiol binding with the estrogen receptor (Knudsen et al. 2011). 
The hER biochemical assay was performed with human estrogen receptor proteins, tritium-
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labeled estradiol, and the test compound up to 50 µM. Changes in radioactivity between no test 
chemical and test chemical determined whether the chemical interfered with estradiol-estrogen 
receptor binding.  
Chemicals with no AC50 value were assigned an arbitrary value of 1M. All AC50 values 
were transformed according to the following formula: 
AC50transformed= -log ! (AC50original) + 6 
This transformed AC50 increases with potency and sets inactive compounds to 0. Compounds 
that were positive in the hER binding assay were tabulated as “Binding” and all others were 
tabulated as “Non-Binding.” Pearson correlation coefficients (r) were calculated for the 
transformed AC50 values between the growth assay and transcriptional activation assays for all, 
binding, and non-binding categories independently.  
Conditional Probabilities 
Conditional probabilities were calculated to determine whether or not chemicals 
classified as positive for ER binding had increased probability of testing positive in the 
ATG_ERa_TRANS, ATG_ERE_CIS, or the T-47D cell growth assay compared to the chemicals 
classified as ER non-binding. Chemicals were split into two categories depending on whether 
they were active in the hER binding assay (Binding), or inactive in the hER binding assays (Non-
Binding). For each of the categories (Binding or Non-Binding) the total number active in either 
0,1,2 or all 3 ER assays (T-47D cell growth, ATG_ERa_TRANS, or ATG_ERE_CIS) was 
divided by the total number of active chemicals in that category to calculate conditional 
probabilities.  
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Logistic Regression Model 
In order to determine if increased potency and efficacy in the T-47D cell growth, 
ATG_ERa_TRANS, and ATG_ERE_CIS increased the likelihood of being positive in the hER 
binding assay, logistic regression was performed using a generalized linear model implemented 
using the R statistical software. The AC50transformed and efficacy normalized to E2 from the cell 
growth assay at 80 h and both transactivation assays were used to model the binary dependant 
variable for ER receptor binding (Binding = 1; Non-Binding=0). Odds ratios were then 
calculated by exponentiating the coefficient for each input variable.  
Sensitivity and Specificity Analysis 
Comparisons were made to results from guideline uterotrophic rodent bioassays and all 
combinations of the T-47D cell growth, ATG_ERa_TRANS, and ATG_ERE_CIS assays. 
Uterotrophic data was captured from EDSP T1S validation and OECD guideline studies. 
Additional details regarding the uterotrophic assays used for this analysis can be found in Rotroff 
et al., (2013). A comparable analysis was performed using 25 ER reference chemicals with 
activities based on NICEATM and literature reports. The list of ER reference chemicals and 
associated calls can be found in Table 3.1. Combinations of all in vitro assays were analyzed to 
determine if adding assays improves capabilities for predicting the uterotrophic or reference 
chemical classifications. All in vitro assays in a given group were required to be active in order 
for the chemical in the corresponding group to be considered active. Sensitivity, specificity and 
balanced accuracies were calculated from counts. A Fisher’s exact test was performed on the 
counts and used to determine the reported p values. 
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Results 
A total of 2016 chemical samples including reference chemicals were screened for effects 
on cell growth. This chemical library included 1816 unique chemicals from the various ToxCast 
libraries and 4 embedded reference compounds. A total of 264 replicated samples consisting of 
69 chemicals were added as duplicates or triplicates, or else were contained in multiple ToxCast 
libraries. The overall concordance of these replicates was 0.84 and 0.89 for cell growth and cell 
loss at 80 h, respectively (Table 3.2). A total of 204 of 1816 chemicals caused increased cell 
growth at 80 h after treatment. The efficacy values ranged from 156% to 28% and the potency 
values spanned the full extent of concentrations tested here. With regards to inhibition of cell 
growth, a total of 360 chemicals were flagged for >25% drop in impedance at 80 h after 
treatment. Maximum inhibition ranged from 26% of the negative control down to 100%. Some 
chemicals caused both an increase in cell proliferation at lower concentrations with higher 
concentrations causing inhibition of cell growth. 
Growth curves were created for all compounds, and Figure 3.2 illustrates representative 
profiles seen throughout the chemical set. Glucocorticoids, mineralocortocoids, and progestins 
caused a distinctive biphasic response profile with an initial increased impedance lasting 
approximately 24 h followed by a return to near baseline growth rates (Figure 3.3A-F), compared 
to the more linear growth curve seen by some androgens and estrogens (Figure 3.3G-I). It should 
be noted however, that some estrogens at high-concentrations also had tendencies to show 
biphasic growth characteristics. A few chemicals, such as 5α-dihydrotestosterone, produced both 
the initial increase followed by a significant linear growth increase at later time points. The 
biphasic response observed for certain endogenous steroid hormones, such as aldosterone, 
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progesterone, and corticosterone, can also be observed for some synthetic steroids. Treatment 
with triamcinolone, a synthetic corticosteroid, and norgesterel, a synthetic progestin, also caused 
biphasic growth responses (Fig. 3C,F). Although some estrogens caused biphasic growth curves, 
such as the synthetic estrogen, 17α-ethinylestradiol, most of these responses had a more linear 
growth profile (Figure 3.2, Figure 3.3G-I). 
The 25 most efficacious compounds can be seen Table 3.3. Several phenolic compounds 
including bisphenol B, bisphenol A, 4,4-sulfonyldiphenol, dodecylphenol, 4-(1,1,3,3-
tetramethylbutyl)phenol, and 4-nonylphenol (branched) were among the most efficacious. 
Though only butylparaben, with a four carbon side-chain, was among the 25 most efficacious 
compounds, the 9 unique paraben chemicals all tested positive except for methylparaben. Results 
from paraben compounds can be seen in Table 3.4. Parabens with longer side-chains appeared to 
be more potent inducers of ER than parabens with shorter side chains.   
In order to determine the concordance among chemical responses across the subset of 
ToxCast ER assays, the potency values (AC50), between the T-47D cell growth assay and two 
ToxCast transcriptional activation assays (ATG_ERa_TRANS, ATG_ERE_CIS) were compared 
(Figure 3.4C). The ATG_ERa_TRANS and ATG_ERE_CIS assays displayed the highest 
correlation across all values with an correlation coefficient of 0.64, indicating that compounds 
‘active’ in one assay were likely to be ‘active’ in the other, and also have similar potency (AC50) 
values between the two assays. This is expected because both are measuring similar, but not 
identical, ER-mediated transcriptional activation. Although, both assays are measuring ER 
transcriptional activity, the ATG_ERE_CIS assay uses a full-length reporter construct, whereas 
the ATG_ERa_TRANS contains only the ligand binding domain. An additional comparison was 
made to determine if there was a difference in correlation between these two transcriptional 
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assays and chemicals that were also positive in the ER binding assay. AC50 values for chemicals 
that were positive for ER binding were highly correlated (r=0.98, p < .001), compared to 
chemicals that were positive in both ER transactivation assays but tested negative for ER binding 
(r=0.59, p < .001) (Figure 3.4C). This suggests that chemicals active for both transactivation 
assays and ER receptor binding have an increased likelihood of activating the ER signaling 
pathway through similar mechanisms, i.e., through ER binding. A complementary analysis was 
performed between the T-47D cell growth assay and each transactivation assay. The cell growth 
assay results demonstrated a weak correlation coefficient of 0.42 (p < .001) and 0.35 (p < .001) 
across all chemicals for ATG_ERE_CIS and ATG_ERa_TRANS assays, respectively (Figure 
3.4A-B). However, when non-binding chemicals were excluded, the correlation coefficient 
increased to 0.70 (p < .001) and 0.72 (p < .001) for ATG_ERE_CIS and ATG_ERa_TRANS 
assays, respectively (Figure 3.4A-B). Because these chemicals were detected as positive for ER 
binding, and were active for both ER transactivation and T-47D cell growth at similar potencies, 
these chemicals would be expected to have a higher likelihood of activating the ER signaling 
pathway through a common mechanism. There were a total of 51 (5%) chemicals that were 
active in the T-47D cell growth assay and both transactivation ER assays out of the available 957 
unique chemicals from ToxCast Phase I and Phase II chemical libraries. There were a total of 20 
(2%) unique chemicals that were considered positive for ER binding, 15 (2%) of which were 
positive for all three cell growth and transactivation assays. Out of the 20 unique chemicals that 
were positive for binding in the hER binding assay, 3 were considered negative in all three cell 
growth and transactivation assays. Overall, this indicates that the hER binding assay is less 
sensitive, but highly specific.  
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Table 3.5 shows the conditional probabilities of being active in the cell growth or 
transactivation assays if also positive in the hER binding assay. Compounds that were negative 
for ER binding have a decreased probability of being active in either the cell growth or 
transactivation assays (Table 3.5). Likewise, compounds active in the hER binding assay have a 
conditional probability of 0.75 for being active in all three cell growth and transactivation assays 
(Table 3.5).     
A logistic regression model revealed that the demonstrated potency (AC50) and efficacy 
(EMAX) for a test compound were highly associated with the likelihood of the compound being 
active in the ER binding assays (p = 3.04x10-7). Odds ratios were calculated using the logistic 
regression coefficients for both the AC50 and EMAX values to determine the contribution of 
each variable for predicting ER binding. Using the AC50 yielded an odds ratio (OR) of 14.57 
(95% CI 3.50 – 109.04), and using the EMAX resulted in a weaker and non-statistically 
significant OR of 1.02 (95% CI 0.96 – 1.07), signifying that chemical potency is a stronger 
indicator of ER receptor binding than efficacy for this set of assays (Table 3.6).     
Results from the uterotrophic sensitivity and specificity analysis are reported in Figure 
3.5. All comparisons were statistically significant (p < .01) and had balanced accuracies (BA) > 
0.7.  The lowest BA was 0.76 for the ATG_ERa_TRANS and the highest BA of 0.815 occurred 
with the T-47D Cell Growth-ATG_ERa_TRANS, T-47D Cell Growth-ATG_ERE_CIS, and the 
T-47D Cell Growth-ATG_ERa_TRANS-ATG_ERE_CIS combinations. Because all assays in a 
group must be positive in order for a chemical to be marked active, sensitivity decreases and 
specificity increases with the addition of assays.  Comparisons to the ER reference set in Table 
3.1 are made in Figure 3.6.  A total of 25 chemicals were available for analysis, including four 
negative compounds (dibutyl phthalate (DBP), flutamide, linuron, progesterone). Overall, the in 
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vitro assays classified compounds more accurately with the ER reference set, than the 
uterotrophic assays.  All assay combinations were statistically significant (p < 0.01) by Fisher’s 
exact tests. The T-47D performed the lowest with a BA of 0.85 (p=0.005). The highest BA 
(0.95) was obtained with the   T-47D Cell Growth-ATG_ERa_TRANS, T-47D Cell Growth-
ATG_ERE_CIS, and the T-47D Cell Growth-ATG_ERa_TRANS-ATG_ERE_CIS 
combinations. 
Discussion 
The results from the present study add an important functional component to measuring 
ER activation, namely T-47D cell growth kinetics, and expand the chemical space to many 
compounds for which no estrogenic information has been thus far captured. 32 (3%) unique 
compounds among 957 test compounds tested negative in all other ER assays, and tested positive 
in the T-47D cell growth assay. This subset of chemicals may have induced T-47D cell growth 
through non-classical ER signaling pathways (Boonyaratanakornkit et al. 2007; Matés et al. 
2008). The other 172 active chemicals would be expected to have a higher likelihood of 
perturbing the estrogenic pathway through more conventional ligand-activated signaling 
network. Comparisons of chemical classifications in the T-47D cell growth assay to chemical 
classifications from uterotrophic studies and ER reference chemicals demonstrated a high-degree 
of concordance (Figures 3.5 and 3.6). Although, all combinations of assays were statistically 
significantly associated with both uterotrophic classifications and ER reference chemical 
classifications, balanced accuracies were generally higher when multiple assays were included. 
One advantage to the real-time capabilities of the xCELLigence platform is the capacity 
to differentiate between chemical growth profiles that may be indistinguishable from testing 
strategies that use traditional proliferation assays with fewer time points.  Biphasic growth curves 
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were observed in some cases, whereby increased impedance occurred, followed by decreased 
impedance around 30 h after compound administration, with a subsequent increase in impedance 
sustained throughout the remaining sampling time. Impedance can be impacted by alterations in 
cell morphology due to cytoskeletal changes and alterations in cellular adhesion machinery, in 
addition to cell proliferation and cell loss (Atienza et al. 2005). The biphasic growth curves 
appeared predominantly after exposures to progestins, mineralcorticoids, glucocorticoids and 
some androgens.  
Two isoforms of the progesterone receptor (PR) have been identified, PRA and PRB, and 
both are expressed in T-47D cells with an approximate ratio of 0.5-0.9 PRA:PRB (Groshong et 
al. 1997; McGowan and Clarke 1999; Sartorius et al. 1994). Activation of PRA is associated 
with morphological changes, such as cell rounding and loss of cell adhesion, and is thought to 
contribute to increased malignancy in tumors expressing high ratios of PRA:PRB; whereas PRB 
is associated with a proliferative response (Boonyaratanakornkit et al. 2007; McGowan and 
Clarke 1999). Biphasic proliferative responses have been observed in T-47D cells expressing 
only the PRB isoform, with increased numbers of cells retained in G2/M+S until approximately 
15-48 h, upon which a late arrest in G1 occurred, roughly corresponding to the biphasic growth 
curves observed in the current study (Figure 3.4) (Boonyaratanakornkit et al. 2007; Groshong et 
al. 1997). Furthemore, PRB has been shown to regulate cell cycle promoters, cyclin D1 and 
cyclin dependent kinase (CDK), and cell cycle inhibitors including p21, in a biphasic manner 
corresponding with late G1 arrest following progesterone exposure (Boonyaratanakornkit et al. 
2007; Groshong et al. 1997). PR, AR, and the glucocorticoid receptor (GR) have been identified 
as inducers of serum and glucocorticoid regulated kinase -1 (SGK-1), which regulates cell 
proliferation and cell cycle progression and may explain the similar growth profile observed by 
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androgens, glucocorticoids, and progestins (Amato et al. 2009; Boonyaratanakornkit et al. 2007; 
Shanmugam et al. 2007). Cyclin D1 has been shown to both activate transcription of ER in the 
absence of estradiol, and be induced by ER transactivation (Altucci et al. 1996; Neuman et al. 
1997; Roy and Thompson 2006). This positive feedback system may explain the sustained 
growth profile observed by estrogen treatments. Though it is not clear what caused the biphasic 
growth profile, T-47D cells do express several steroid hormone receptors, and hormones are 
known to impact cell cycle through both receptor-mediated and receptor-independent 
mechanisms. In addition, electron transport chain inhibitors, pyridaben and rotenone, also 
potently induced cell growth in this assay. An ancillary experiment was conducted that 
demonstrated, unlike estradiol, the growth induced by these compounds was not attenuated by 
the ER antagonist, ICI 182,780. The inability for ICI 182,780 to block the proliferative response 
indicates that these compounds are not inducing cell growth through an ER mechanism (Figure 
3.7). 
Many of the most efficacious compounds in the T-47D cell growth assay included 
phenolic compounds (Table 3.3). The ability for phenolic compounds to bind and activate ER 
has been demonstrated in a number of studies (Blair et al. 2000; Gaido et al. 1997). Some 
phenolic compounds, such as bisphenol-A and 4-nonylphenol are high-production volume 
(HPV) chemicals used in a wide variety of applications, including food and drink packaging, 
flame retardants, polycarbonate plastics, detergents, and polystyrene tubes (Calafat et al. 2005; 
Sonnenschein and Soto 1998; U.S. HHS 2008). Potential for human exposure to these HPV 
chemicals is relatively high due to their use in a wide range of manufacturing applications. 
Bisphenol-A, for example, has been detected in blood and urine samples ubiquitously in the 
population (Calafat et al. 2005). Although the estrogenic potential of compounds like bisphenol-
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A and 4-nonylphenol has been previously studied, limited data exists on the potential 
estrogenicity for many chemicals tested in this chemical library, such as butam. Butam is an 
herbicide that tested positive in the T-47D cell growth, ATG_ERa_TRANS, and ATG_ERE_CIS 
assays.    
  The paraben chemical class is composed of commonly used preservatives found in a wide 
range of household items, some of which include cosmetics, shampoos, pharmaceuticals, and 
food additives (Smith et al. 2012). Parabens have demonstrated activity in a variety of ER assays, 
and an increased paraben side chain length positively correlates with ER activation potency 
(Blair et al. 2000; Okubo et al. 2001). This was highly consistent with the T-47D cell growth 
assay described herein, in which parabens with longer side chains achieved greater potency than 
parabens with shorter side chains (Table 3.4). Relative efficacies for most of the parabens were 
between 60% and 90% of estradiol, but no structurally-related trend for efficacy was apparent. 
Parabens all demonstrated linear growth profiles, suggesting the activation of different pathways 
compared to the compounds associated with biphasic growth profiles.     
The ratio of ERα to ERβ is an important factor to determining the phenotypic response 
after estrogenic exposure (Gustafsson 1999; Kuiper et al. 1997; Pravettoni et al. 2007). 
Genistein, a naturally occuring phytoestrogen, resulted in a growth response similar to 17β-
estradiol, albeit less potent; however, genistein has been associated with decreased cell 
proliferation in certain cell lines, e.g., Caco2-BBe, MCF-7, and PC-3 (Chen and Donovan 2004; 
Peterson and Barnes 1996). Although, genistein may bind to ERα, it preferentially binds to ERβ 
(Kuiper et al. 1997). ERβ has been shown to counter the proliferative response typically 
associated with ERα activation (Gustafsson 1999; Pravettoni et al. 2007). T-47D cells have a 
much higher basal ERα/ ERβ ratio, resulting in increased proliferation after genistein exposure 
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(Sotoca et al. 2008; Strom et al. 2006). Sotoca et al. (2008) used a T-47D-ERβ recombinant cell 
line with enforced expression of ERβ and managed to attribute the observed anti-proliferative 
effect to ERβ activation. This suggests that the high ratio of ERα: ERβ in T-47D cells is the 
likely cause for the observed proliferative response by genistein in this study. In addition to the 
impact of ERα to ERβ ratios, cofactor availability may be tissue and cell type dependent, and 
could alter the observed response (Shang et al. 2000; Thenot et al. 1999).  
The high-throughput hER binding assay is less sensitive compared to the T-47D cell 
growth, ATG_ERa_TRANS, and ATG_ERE_CIS assays (Figure 3.4). The hER binding assays 
were exposed to chemical concentrations of up to 50 µM, and the T-47D cell growth, 
ATG_ERa_TRANS, and ATG_ERE_CIS assays were tested with chemical concentrations up to 
100 µM. This provides a partial explanation for why the hER binding assays did not detect the 
weakly active compounds; however, many of the chemicals that were positive in the T-47D cell 
growth, ATG_ERa_TRANS, and ATG_ERE_CIS assays produced AC50 values < 50 µM and 
were not detected in the hER binding assay. The cross-assay comparisons provide a better 
understanding of each assay’s strengths and weaknesses in order to better characterize an 
individual chemical’s estrogenic potential.  
When considered in context of other ER in vitro assays, the T-47D cell growth assay 
provides an important functional measurement of estrogenic activity. This assay may be an 
important indicator for non-genomic mechanisms of ER activation; the importance of these 
mechanisms in regulating proliferative responses are becoming increasingly apparent 
(Björnström and Sjöberg 2005; Falkenstein et al. 2000; Watson et al. 2011). It is possible that 
some of the discrepancies between active and inactive responses between the cell growth assay 
and the two transcriptional activation assays may be due to an estrogenic response not mediated 
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by gene expression through the estrogen response element. Future work is needed to include a 
more comprehensive panel of assays, covering other key molecular initiating events in the ER 
pathway. Currently, efforts within the ToxCast program are underway to include assays that 
measure ER signaling before and after treatment of the test chemical with a liver S9 fraction to 
determine effects of xenobiotic metabolism and to include assays that measure receptor 
dimerization and nuclear translocation for both ERα and ERβ. Overall, the T-47D cell growth 
assay provides important information relating duration of exposure, potency, and efficacy to 
effects on cell growth or cell loss. In addition, the data-driven characterization of ER in vitro 
assays provides an important step towards developing a more comprehensive and integrated 
approach for testing chemicals for their potential modulation of ER signaling.   
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Tables 
Table 3.1. ER Reference Chemicals for Sensitivity and Specificity Analysis. 
 
CASRN Chemical Name Activity Call 
57-63-6 17alpha-ethynyl estradiol Positive 
50-28-2 17beta-estradiol Positive 
56-53-1 Diethylstilbestrol (DES) Positive 
77-09-8 Phenolphthalein Positive 
140-66-9 
4-(1,1,3,3-
Tetramethylbutyl)phenol Positive 
599-64-4 4-Cumylphenol Positive 
80-05-7 Bisphenol A Positive 
77-40-7 Bisphenol B Positive 
85-68-7 Butylbenzyl phthalate Positive 
94-26-8 Butylparaben Positive 
60168-88-9 Fenarimol Positive 
446-72-0 Genistein Positive 
143-50-0 Kepone Positive 
84852-15-3 Nonylphenol (branched) Positive 
789-02-6 o,p'-DDT Positive 
120-47-8 Ethylparaben Positive 
1912-24-9 Atrazine Positive 
56-55-3 Benz[a]anthracene Positive 
115-32-2 Dicofol Positive 
72-43-5 Methoxychlor Positive 
72-55-9 p,p’-DDE Positive 
84-74-2 Dibutyl phthalate (DBP) Negative 
13311-84-7 Flutamide Negative 
330-55-2 Linuron Negative 
57-83-0 Progesterone Negative 
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Table 3.2. Chemical Library Results Summary and Replicate Concordance   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemical 
Library 
No. 
Chemical 
Samples 
No. 
Unique 
Chemicals 
No. Active 
Chemicals - 
Cell 
Growth 
Percentage 
Active - Cell 
Growth (%) 
Replicate 
Concordance -
Cell Growth 
No. Active 
Chemicals - 
Cell Loss 
Percentage 
Active - Cell 
Loss (%) 
Replicate 
Concordance 
- Cell Loss 
Phase Iv2 311 293 16 5.5 0.96 74 25.3 0.96 
Phase IIab 700 676 81 12.0 0.78 130 19.2 0.82 
E1K 1000 880 123 14.0 0.88 156 17.7 0.92 
Total 2016a 1820a,b 204 11.2 0.84 360 19.8 0.89 
a
 Four Additional reference chemicals were included 
b
 Some compounds were run in more than one chemical library 
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Table 3.3. 25 Most Potent and Efficacious Compounds in the Cell Growth Assay at 80 h.  
 
CASRN Chemical Name Time Since Treatment (h) 
Time Since 
Treatment 
When First 
Active (h) 
AC50 
(µM)a 
EMAX (% 
E2) 
EMIN 
(% E2) 
Response Cutoff for 
Activity (% Growth above 
Starting Value) 
77-40-7 Bisphenol Bb 80.0 46.2 0.283 128.93 25.28 47.45 
50-28-2 17beta-Estradiolb 79.8 44.9 ≤0.006 128.72 84.56 59.66 
57-91-0 17alpha-Estradiol 80.0 44.0 ≤0.006 127.35 92.59 49.76 
446-72-0 Genisteinb 79.7 48.9 0.082 123.09 34.56 46.99 
27193-86-8 Dodecylphenol 80.1 44.1 0.229 117.50 41.08 57.00 
80-05-7 Bisphenol Ab 79.5 47.1 0.387 116.70 32.73 51.63 
84-16-2 meso-Hexestrol 79.7 46.7 ≤0.006 115.46 93.70 56.14 
57-63-6 17alpha-Ethinylestradiolb 79.7 13.7 ≤0.006 114.87 104.75 47.14 
72-33-3 Mestranol 80.1 41.3 ≤0.006 114.18 89.55 54.32 
84852-15-3 4-Nonylphenol, branchedb 80.0 46.4 0.304 110.94 26.33 48.34 
17924-92-4 Zearalenone 80.0 52.1 0.022 109.84 64.00 64.34 
105624-86-0 5HPP-33 79.8 49.9 0.386 108.81 20.47 48.04 
53-16-7 Estrone 79.5 52.4 ≤0.006 105.17 85.66 51.97 
474-86-2 Equilin 79.7 50.0 ≤0.006 103.63 79.63 53.64 
2971-36-0 
2,2-Bis(4-hydroxyphenyl)-1,1,1-
trichloroethane 79.7 50.7 0.102 101.65 35.61 57.65 
521-18-6 5alpha-Dihydrotestosterone 79.6 43.1 0.181 100.35 45.01 55.11 
50-27-1 Estriol 80.1 56.4 ≤0.006 97.87 78.38 49.36 
56-53-1 Diethylstilbestrolb 79.0 48.0 ≤0.006 95.87 87.12 46.46 
486-66-8 Daidzein 79.5 56.1 0.400 90.25 30.34 54.21 
68-22-4 Norethindrone 79.9 40.9 ≤0.006 89.26 53.55 51.56 
1478-61-1 Bisphenol AF 79.7 52.1 0.118 88.41 30.88 55.79 
10161-33-8 17beta-Trenbolone 79.7 40.7 ≤0.006 88.21 59.43 55.57 
140-66-9 4-(1,1,3,3-Tetramethylbutyl)phenol 79.7 52.0 0.230 82.83 26.68 49.09 
57-83-0 Progesterone 79.8 43.8 0.079 77.86 48.35 49.06 
104-43-8 4-Dodecylphenol 80.0 65.0 0.244 75.21 20.90 60.22 
a Compounds that were saturated at lowest concentration tested are denoted with “≤”  
b
 Compounds that were present in multiple chemical libraries, the one with the highest EMAX was included in this table. 
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Table 3.4. Paraben Compounds – T-47D Cell Growth Potency and Efficacy at 80 h   
Table 3.5. Estrogen Receptor Binding Conditional Probabilities 
 
 
 
 
 
CASRN Chemical Name 
Time Since 
Treatment 
(h) AC50 (µM) 
EMAX 
(% E2) 
Response Cutoff for Activity 
(% Growth above Starting 
Value) 
5153-25-3 2-Ethylhexylparaben 80.1 0.607 82.55 54.08 
1219-38-1 Octylparaben 80.1 1.143 90.91 54.32 
17696-62-7 Phenylparaben 80.1 1.332 65.78 54.08 
1085-12-7 Heptylparaben 79.9 1.492 82.94 50.21 
94-26-8 Butylparabena 80.0 1.776 99.23 51.39 
94-18-8 Benzylparaben 80.1 1.871 69.70 61.94 
94-26-8 Butylparabena 79.7 3.426 116.36 53.61 
94-13-3 Propylparaben 80.0 4.329 88.88 49.14 
120-47-8 Ethylparabena 80.1 7.617 63.35 52.77 
120-47-8 Ethylparabena 80.1 7.860 65.69 52.78 
99-76-3 Methylparaben 80.0 NA 40.98 49.14 
a Chemical was included in two different ToxCast chemical inventories 
No. of Assays 
Detected as 
Activea 
No. 
Chemical
s Detected 
as ER 
Bindersb 
Conditional 
Probability for 
Binders 
No. Chemicals 
Detected as ER 
Non-Bindersb 
Conditional 
Probability for Non-
Binders 
0 3 0.15 664 0.70 
1 1 0.05 152 0.16 
2 1 0.05 93 0.10 
3 15 0.75 36 0.04 
a
 Assays include T-47D Cell growth, ATG_ERa_TRANS, and ATG_ERE_CIS;  b Based on the hER binding assay 
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Table 3.6. Logistic Regression Model Performance   
Input 
Variable 
No. 
Chemical
sa 
Coefficient
s (β) 
Std. 
Error 
Odds Ratio  
(95% CI)  P-value 
Intercept 51 -16.90 4.84 
4.16x10-8 (5.23x10-13 – 
8.72x10-5) 0.0004 
Mean 
Efficacy 
(EMAX) 51 0.02 0.03 1.02 (0.96 – 1.07) 0.53 
Mean 
Potency 
(AC50) 51 2.68 0.86 14.57 (3.50 – 109.04) 0.0012 
Overall 
Model 51    3.04x10-7 
a
 Only chemicals active in all three assays were used (Cell growth, ATG_ERa_TRANS, and ATG_ERE_CIS) 
 
 89
 
Figures 
Figure 3.1. RTCA Cell Growth Assay. 96-well E-plates have electrodes at the bottom of each 
well. Cells are seeded and the impedance signal is altered by the confluence or morphological 
changes of cells in each well. Increases in cell density correspond to increased impedance (Z). 
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Figure 3.2. Example of Growth Curve Translation to Concentration Response Curve. In this example, the effect of treatment with 
genistein on cell proliferation was plotted over time and concentration. As the cell number increased, the impedance increased. The 
treatment had an apparent effect on cell growth or viability which can be measured through the relative decrease in electrical 
impedance. The circles on the growth curve correspond to the time of the concentration response curve plotted on the bottom. 
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Figure 3.3. Representative growth curves of various test compounds measuring changes in 
normalized cell index (NCI) over time (h). Biphasic growth curves can be seen for some 
endogenous and synthetic steroid hormones including corticosteroids (B,F), progestins (A,C), 
and some androgens (D,E), whereas linear growth curves are observed for compounds known to 
bind to the estrogen receptor (ER) (G-I).    
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Figure 3.4. Comparison of Cell Growth Results with Additional ER Assays. Chemical AC50 
values were log transformed so that the axis increases with potency. The potency values were 
compared with two transactivation assays (ATG_ERa_Trans and ATG_ERE_CIS). Chemicals 
positive for one of three ER binding assays were colored red, and chemicals testing negative in 
all three binding assays were colored red. Linear regression demonstrated a higher linear 
correlation between compounds that were also detected to bind to ER. 
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Figure 3.5. Receiver operating characteristic (ROC) plot for uterotrophic comparisons. 
Symbols represent groups of assays. A chemical must be classified as active in all assays in 
the given group for a chemical to be considered active. Active and inactive chemicals were 
then compared to classifications of uterotrophic activity to determine sensitivity, specificity, 
and BA. P values were determined by Fisher’s exact test.    
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Figure 3.6. ROC plot for ER reference chemical comparisons. Symbols represent groups of 
assays. A chemical must be classified as active in all assays in the given group for a chemical 
to be considered active. Active and inactive chemicals were then compared to classifications 
of uterotrophic activity to determine sensitivity, specificity, and BA. P values were 
determined by Fisher’s exact test. 
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Figure 3.7. Combination Treatment of Electron Transport Chain Inhibitors with ER 
Antagonist, ICI 182,780. Two known mitochondrial electron chain inhibitors, rotenone and 
pyridaben, caused a potent increase in the Normalized Cell Index (NCI). In order to 
investigate if this observation was occurring through the activation of ER, the study was 
repeated using a combination of chemical treatment alone, and chemical treatment in 
combination of prototypical ER antagonist, ICI 182,780. The response induced by 17β-
estradiol was completely attenuated with the addition of ICI 182,780. However, addition of 
ICI 182,780 had no effect on the response induced by rotenone or pyridaben treatment, 
suggesting the response causing increased impedance is not mediated by ER.  
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CHAPTER 4 
ENDOCRINE TESTING IN THE 21ST CENTURY: USING IN VITRO ASSAYS TO PREDICT 
ESTROGEN RECEPTOR SIGNALING RESPONSES 
 
 
Introduction 
 The estrogen receptor (ER) regulates a vast array of physiological responses through a 
highly complex network of signaling mechanisms. Disruption of ER signaling or estrogen 
biosynthesis has been shown to cause adverse effects on reproductive success and fetal 
development, and can exacerbate certain types of cancer (Bigsby et al. 1999; Birnbaum and 
Fenton 2003; Cooper and Kavlock 1997; Kavlock et al. 1996; Mahoney and Padmanabhan 2010; 
Soto and Sonnenschein 2010). New research, still in its infancy, is also demonstrating the 
important role of ER in healthy neurological functioning (Isoe-Wada et al. 1999; Sampei et al. 
2000; Tan et al. 2012; Xin et al. 2012). The significant role of ER and its involvement in a 
diverse set of health effects has led to a large body of scientific research focused on elucidating 
ER’s intricate pathway.  
Activation of ER signaling has been demonstrated by some environmental chemicals, 
(e.g. bisphenol-A, parabens); however, thousands of chemicals exist with little to no data 
regarding their toxicological potential (Judson et al. 2009). In 1996, the U.S. Environmental 
Protection Agency (EPA) was tasked with screening chemicals for their potential to interact with 
estrogen, androgen, steroidogenesis, and thyroid mechanisms(U.S. EPA 2012). In response, the 
EPA created the Endocrine Disruptor Screening Program (EDSP) with the aim of testing the 
many thousands of chemicals for endocrine disrupting potential using a two-tiered testing 
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strategy. Thousands of chemicals are subject to Tier 1 screening (T1S), at an estimated cost of 
~$1 million per chemical (U.S. EPA 2011a, 2011b). The initial list of 67 chemicals was finalized 
in 2009 and has yet to complete T1S. Due to the prohibitive costs of testing all necessary 
chemicals, EPA has launched the EDSP21 project with the immediate goal of chemical 
prioritization using computational and in vitro approaches, and the long-term goal of replacing 
more resource-intensive T1S assays with cost effective testing strategies. 
One hypothesis is that by using multiple in vitro assays measuring orthogonal targets in a 
signaling pathway, one gains increased confidence in a chemical’s potential to perturb the given 
pathway. However, this is complicated by the fact that biological implications of ER activation 
are heavily dependent on cell and tissue type, and in vitro assays are tested using a variety of 
technologies in multiple cell types (Kolasa et al. 2003; Saunders et al. 2002). For example, the 
two isoforms of ER (ERα and ERβ) result in somewhat opposite physiological effects. ERα 
activation generally results in a proliferative response, whereas, ERβ activation generally results 
in an anti-proliferative and anti-inflammatory response (Gustafsson 1999; Pravettoni et al. 2007). 
Chemicals that bind to ER will oftentimes bind to both isoforms but with differential affinities 
(Kuiper et al. 1997). Furthermore and contrary to traditional thought, a growing body of 
evidence suggests that many ER ligands are not easily classifiable as agonists or antagonists, but 
that weak/partial agonists can act as antagonists under certain conditions (Dutertre and Smith 
2000). Therefore, it is critical for any modeling effort where a key component is the aggregation 
of assay results, to incorporate the distinct biological characteristics of individual assays in order 
to obtain a biologically relevant model. Development of the model was built around the 
conceptual ER signaling pathway in Figure 4.1. 
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In the present study, we used an aggregation of in vitro assay results to develop an ER 
interaction score, indicating the likelihood of a chemical interacting with ER, the process by 
which the model was constructed and evaluated is shown in Figure 4.2. We used distinct assay 
characteristics to form chemical-activity spectrums for putative ERα/ERβ and 
antagonism/agonism responses. One challenge to developing this model was the limited number 
of chemicals available for comparison; nevertheless, model comparisons with available in vivo 
data and ER reference chemical classifications indicate that the model is capable of predicting 
estrogenic likelihood with a high degree of accuracy. 
 
Methods 
Chemical Selection  
 The present study was conducted using data from three ToxCast chemical libraries which 
consisted of 1800 unique chemicals. This inventory includes 293 chemical structures from the 
Phase Iv2 ToxCast chemical library, the majority of which are active ingredients of current or 
former food-use pesticides, or industrial chemicals of environmental relevance (Judson et al. 
2009). An additional 676 chemical structures were from the ToxCast Phase II chemical library. 
The remaining 880 chemical structures were from the ToxCast E1K chemical library. Individual 
chemical library information can be found at http://www.epa.gov/ncct/toxcast/chemicals.html. 
All chemicals were shipped as 20mM stock solutions in DMSO. 
In Vitro Assays 
 The NovaScreen HTS competitive binding assays for human, bovine, and mouse estrogen 
receptor (hER, bER, mERa, respectively) were developed and run by Caliper Discovery 
Alliances and Services (Hanover, MD). A more complete description of the large set of HTS 
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assays from which these are taken is provided in Knudsen et al. (2011). The hER, bER, mERa 
receptor binding assays (Catalog Nos. 100-0127, 100-0126, 100-0897) were conducted on 
extracts of human breast cancer cells, bovine, and mouse uterine membranes, respectively. The 
ER radioligand assays measure displacement of [3H]-estradiol at final ligand concentrations of 
0.1 nM (hER) and 0.7 nM (bER) with the positive reference 17β-estradiol. Reactions were 
carried out in 10 mM TRIS-HCI (pH 7.4 containing 1.5 mM   EDTA, 1.0 mM dithiothreitol and 
25 mM sodium molybdate at 0-4 ºC for 18 hr. The reaction is terminated with dextran-coated 
charcoal and incubated for 20 min at 0-4 ºC to adsorb unbound radioactivity. After 
centrifugation, the radioactivity remaining bound in the supernatant fraction is determined and 
compared to reference control values in order to ascertain any interactions of test compound with 
the ligand-binding site. The competitive binding assays were initially run in duplicate at a single 
concentration. Assay-chemical combinations meeting a pre-defined threshold of 30%, from the 
vehicle (DMSO) control signal or if the Z score was at least 2.0 median absolute deviations from 
the median (30% inhibition or MAD2) were then run in a follow-up screen in singleton 
concentration–response format with maximum concentration of 50µM (Knudsen et al. 2011). 
Concentration response curves in the follow-up screen constrained the upper and lower 
asymptotes of the curve between 0- and 20% activity and between 100- and 120% activity, 
respectively, to allow for consistent extrapolation of the concentration at 50% activity (AC50) 
across assay-chemical combinations. Extrapolated AC50s above the highest concentration tested 
were allowed if the Emax was greater than 25% activity. Emax is defined in this analysis as the 
maximal tested response minus the lower asymptote. In order for a response to report an AC50 
and be established as a hit, an Emax of 25% and an R-squared filter of 0.5 must be obtained 
(Knudsen et al. 2011). 
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The Odyssey Thera assays utilizes protein-fragment complementation assay (PCA) 
technology which consists of a reporter protein rationally dissected into two fragments and fused 
to two proteins known to interact within a signaling complex. The reporter protein is fully 
assembled when the two test proteins dimerize. Chemical activity is measured via changes in 
signal intensity and location. For the assays in the present study, the fused proteins were 
expressed in human HEK293T kidney cell lines and target estrogen receptors alpha (ERα) and 
beta (ERβ) homo- and heterodimerization. Assays were run at 24 h across three dimerization 
conditions (ERα-ERα, ERα-ERβ, ERβ- ERβ) and represent assays, OT_ERaERa_1440, 
OT_ERaERb_1440, OT_ERbERb_1440, respectively. Normalization of assay results was 
performed as percent of the 17β-estradiol, and the baseline for each plate-wise normalization was 
the median raw plate response including all DMSO wells. Concentration response data was fit to 
a Hill model with criteria for generating AC50 values including: Hill curves R2values ≥ 0.5, p-
value ≤ 0.01 (from a test of significant difference between the top and bottom of the curve fit), 
and Emax (maximum activity) ≥ 30% baseline activity.  
The Attagene assays describe a large collection of transcription factor assays, including 
two ER assays (ATG_ERa_TRANS, ATG_ERE_CIS). This collection of a multiplexed reporter 
gene assays and data on 309 environmental chemicals are described in Martin et al. (Martin et 
al., 2010). Attagene Inc. (RTP, NC), under contract to the U.S. EPA (Contract Number EP-W-
07-049), provided multiplexed reporter transcription unit (RTU) assays consisting of 48 human 
transcription factor DNA binding sites transiently transfected into the HepG2 human liver 
hepatoma cell line (Romanov et al. 2008). In addition to the Cis-acting reporter genes (CIS), a 
modification of the approach was used to generate a trans-system (TRANS) with a mammalian 
one-hybrid assay consisting of an additional 25 RTU library reporting the activity of nuclear 
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receptor (NR) superfamily members  (Martin et al. 2010).The human ligand-binding domain of 
each nuclear receptor was expressed as a chimera with the yeast GAL4 DNA-binding domain 
that activated in trans a 5XUAS-TATA promoter, which regulated the transcription of a reporter 
sequence unique to each NR RTU. To ensure the specificity of detection, each individual trans-
RTU system including both receptor and reporter gene was separately transfected into suspended 
cells followed by pooling and plating of the transfected cells prior to screening. A major 
difference between the CIS and TRANS system is that in CIS activities of endogenous 
transcription factors are measured, whereas the TRANS assay evaluates changes in activities of 
exogenous, chimeric NR-Gal4 proteins. A cytotoxicity assessment was performed at the higher 
concentrations, qualitatively, to remove confounding data from the downstream analysis process. 
Additional details on how the cytotoxicity assessment was performed are provided in Rotroff et 
al. (Rotroff et al. 2013a). 
The ACEA data (ACEA_T47D_80hr_Positive )was generated using the xCELLigence 
system Multi-E-Plate stations which measure the time-dependent growth response by real-time 
cell analysis. All screening was carried out by ACEA Biosciences, Inc. (San Diego, CA). T-47D 
cells purchased from ATCC were maintained in RPMI1640 media supplemented with 10% 
characterized fetal bovine serum (FBS). Before screening, T-47D cells were pre-conditioned in 
assay medium: Phenol Red-free RPMI1640 supplemented with 10% charcoal-stripped FBS. 
Cells were then detached and seeded in E-Plates 96 in assay medium. Cellular responses were 
then recorded once every 5 min for the first 5 hours, and once every hour for an additional 100 
hours. Each chemical was tested in an eight-point, 1:4 serial dilution series starting at a 
maximum final concentration of 100 µM. A maximum starting concentration of 0.5% DMSO 
was present in the 100 µM chemical samples and was diluted along with the test article dilution 
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series. The screen was performed in biological duplicate using two separate, 96-well, E-Plates 
96TM for each dilution series (n=2). Positive control, 17β-estradiol, was tested in quadruplicate 
on each testing plate. 0.5% and 0.125% DMSO were tested in duplicates in each plate to serve as 
solvent controls for the 2 highest concentrations of testing compounds: 100 µM and 25 µM. 
Reference compounds were tested with 8 concentrations with 1:5 serial dilutions. Raw data were 
collected in the form of Cell Index (CI) for each of the time points before and after compound 
addition.  All data was normalized to the CI value at the time of compound administration. 
Following background subtraction of the DMSO solvent control, the values were represented as 
% of 17β-estradiol based on the positive and negative controls on each plate. For the present 
study, only the 80 h time point was used for incorporation into the model.  Cytotoxicity was 
ascribed to a particular chemical-concentration level when the response fell below 15% of the 
next lower test concentration. This concentration and all higher concentrations were flagged and 
excluded from the concentration response data prior to concentration response curve fitting. If 
the upper asymptote of the concentration response curve reached 25% of 17β-estradiol, then the 
chemical was assessed as ‘active’ for T-47D cell growth. Additional details of the ACEA data 
processing and analysis can be found in Rotroff et al. (Rotroff et al. 2013a). 
The Tox21 assays consist of two high-throughput ER reporter gene assays run in both 
agonist and antagonist mode. GeneBLAzer® ERα-UAS-bla GripTiteTM cell line was obtained 
from Invitrogen (Carlsbad, CA, USA). Each of these lines stably express the ligand-binding 
domain (LBD) of the specific human nuclear receptor fused to the DNA-binding domain (DBD) 
of GAL4 and  a beta-lactamase reporter gene under the transcriptional control of an upstream 
activator sequence (UAS). Binding of agonist to the LBD of the GAL4 (DBD)-NR (LBD) fusion 
protein causes the fusion protein to bind to the UAS, resulting in expression of beta-lactamase. In 
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antagonist mode, an AC50 concentration of the reference ligand was included in the assay. Cells 
were cultured in medium containing 2% charcoal/dextran-treated FBS, 0.1 mM NEAA and 1 
mM sodium pyruvate overnight in the flasks before the assay. The assay was performed in clear 
bottom black Greiner 1536-well plates. 17β-estradiol was used as a positive control. Library 
compounds were measured for their ability to either stimulate or inhibit (in the presence of an 
AC50 of the appropriated agonist) the reporter gene activity. Compounds were screened in a 15-
point titration series from 1 nM to 76 µM in 1536-well format and reporter gene activity 
determined as previously described (Huang et al. 2011). Data were normalized relative to 
positive controls (20 nM, 100%, for agonist mode and 0.5nM, 0%, for antagonist mode), and 
DMSO-only wells (basal, 0% for agonist mode and -100% for antagonist mode). Concentration-
response titration points for each compound were fitted to the Hill equation yielding 
concentrations of half-maximal stimulation (EC50), half-maximal inhibition (IC50) and maximal 
response (% of control) values (Huang et al. 2011). For agonist activity, the maximal response 
needed to be at least 20% of the maximal response of the positive control to be considered 
agonist activity.  
Data Processing 
Concentration response curves were aggregated according to their assigned group within 
the ER pathway(Figure 4.1 and Table 4.1). The NVS_hER, NVS_mERa, and NVS_bER binding 
assays were grouped together because both agonist and antagonist activity are detectable and 
indistinguishable. Agonist assays, OT_ERaERa_1440, OT_ERaERb_1440, OT_ERbERb_1440, 
Tox21_ERa_BLA_agonist, Tox21_ERa_LUC_BG1_agonist, ATG_ERa_TRANS_perc, and 
ATG_ERE_CIS_perc were grouped together. Antagonist assays, Tox21_ERa_BLA_antagonist 
and Tox21_ERa_LUC_BG1_antagonist were grouped together. Because the ACEA_T47D_80h 
 109
assay responds to growth inducing chemicals other than estrogens, it was given a group of its 
own (Rotroff et al. 2013a). Groups of assays are annotated in Figure 4.1 and tabulated in Table 
4.1.  
In order to minimize the variability occurring from different assay technologies, assays 
within groups were linearly transformed. Linear transformation was performed by selecting an 
anchor assay, and selecting a potent and weak reference chemical that was positive in all assays 
within the group. The AC50 value was used as the point of reference for the transformation. 17b-
estradiol and benzyl butyl phthalate were used as reference chemicals for the agonist group. For 
the antagonist group, fulvestrant was used as the potent reference chemical and no weak 
reference chemical available. Because two points are required for the linear transformation, a 
dummy chemical was created for the weak reference in the antagonist group, and was given a 
value of 100 µM for each assay. Therefore, no transformation occurred for chemicals active at 
high concentrations, but appropriate adjustments were made at lower concentrations. For each 
group, the differences between the anchor assay’s AC50 and each individual assay’s AC50 for 
the two reference chemicals were fit using a linear regression model, and the subsequent slope 
and intercept were used as correction factors and applied across all chemicals in the given group.  
This transformation does not adjust the shape of the concentration response or the y-axis. The 
only adjustments made are adjustments to the x-axis, so that chemicals can be adequately 
compared across assays. No transformation was applied to the binding assays since they are 
tested using the same technology platform, or the cell growth group because it is composed of a 
single assay.  
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Composite Concentration Response Curves 
All chemicals for each assay technology were fit using non-linear least squares regression 
to a hill-model in a separate analysis, as previously described. These analyses included filtering 
for cytotoxicity and outliers where applicable. All assay responses were normalized to 17β-
estradiol, except those in the antagonist group, which were normalized to 4-hydroxytamoxifen. 
Next, non-linear least squares regression in the open-source statistical software, R and the 
sfsmisc package were used to fit a single, composite concentration response curve through all 
individual concentration response curves for a given group using a hill-model (Maechler 2011; R 
Development Core Team 2011). A representation of a composite model can be seen in Figure 
4.3. The four-parameter Hill equation is represented as: 
 =  −  − 
1 +  50
 
 T was constrained to +/- 20% of the maximum response observed across all assays in the 
group in order to minimize convergence errors. B was constrained to 0, and W was constrained to 
1. In order to determine the uncertainty around the composite model, 100 composite models were 
generated by sampling individual assays with replacement. Each size of each sample was 
consistent with the number of unique assays, and a composite model was fit through each 
sample. A 99% confidence interval of the bootstrapped samples was calculated at each 
interpolated concentration. Because the growth group only contained a single assay, a 90% 
prediction interval was calculated from the sum of squared errors. In order to obtain uncertainty 
estimates when there were not enough data points available to calculate the prediction interval 
within the growth group, interpolated data points were added to the response but were weighted 
so that they did not impact the error calculation.  
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The Efficacy Score (%) is calculated from the maximum value of the lower-window of 
the bootstrapped confidence interval. If the window does not overlap with zero, then a response 
is considered to have statistically significant response and will have an Efficacy Score > 0. If the 
maximum value of the lower-window overlaps with 0, then the Efficacy Score will equal 0. The 
first concentration at which the lower window of the confidence interval was greater than zero 
was annotated as the lowest effective concentration (LEC) (µM). The Potency Score (%) was 
obtained by taking the lowest and highest concentrations across all chemicals as 100% and 0%, 
respectively, and calculating the percentage at which the LEC occurs. If the lower-window of the 
confidence interval never increased above 0, then the Potency Score was set to 0. A separate 
ERα and ERβ Potency Score was calculated using the AC50 from the OT_ERaERa_1440 and 
the OT_ERbERb_1440, respectively. 
If both the Potency and Efficacy Scores were > 0, then the mean of the Potency Score and 
the Efficacy Score was assigned as the Composite Score for the chemical-group. Otherwise the 
Composite Score is set to 0. A graphical representation of these parameters is shown in Figure 
4.3. Composite Scores were then scaled to the maximum Composite Score within each group. If 
all individual assays within a group were active for a chemical, but the composite score was 0, 
then the chemical was flagged for follow-up analysis.  
The ER Interaction Score is calculated based on the following logic:  
(1) IF: #$%&'() > 0		,	#$%&'() > #$')$%&'() 
    THEN: -.	/0123405/	#4521 = #$%&'() +	#6'7'% +	#%8&9):/3   
(2) IF: #$')$%&'() > 0		,	#$')$%&'() > #$%&'() 
    THEN: -.	/0123405/	#4521 = #$')$%&'() +	#6'7'%/2   
(3) IF: <#$%&'() = 0=	,	<#$')$%&'() = 0=,#6'7'% > 0  
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     THEN: -.	/0123405/	#4521 = #6'7'% +	#%8&9): + 	0/3   
(4) IF: <#$%&'() = 0=	,	<#$')$%&'() = 0=,#6'7'% = 0  
     THEN: -.	/0123405/	#4521 = 0   
Where CSagonist is the scaled agonist Composite Score, CSantagonist is the scaled antagonist 
Composite Score, CSbinding is the scaled binding Composite Score, and CSgrowth is the scaled 
growth Composite Score.  
Hierarchical Clustering  
Hierarchical clustering was performed using the “pheatmap” package in statistical 
software, R (R Development Core Team 2011; Raivo Kolde 2012). Two separate heatmaps were 
generated, one with all chemicals, and one with only chemicals that had Composite Scores > 0 
for at least one group (binding, agonist, antagonist, or growth). Clustering was performed using 
Euclidean distance and Ward’s method. 
Model Evaluation  
The impact of the linear transformation was determined by comparing the distributions of 
R2 values from all chemicals in the agonist and antagonist groups, respectively, with and without 
the linear transformation. Statistical significance was determined using a one-tailed Wilcoxon 
test (α= 0.05). The analysis was also repeated with only chemicals that produced ER Interaction 
Scores > 0.    
Model stability for the agonist group was tested by comparing the CSagonist  after 
removing a single assay and was then repeated for each assay. Each model with a single assay 
removed was compared to the model with all assays by fitting a linear regression model to the 
two sets of CSagonist. The percentage of compounds with CSagonist > 0 was recorded, and R2 and 
linear regression (p < 0.01) were used to characterize the goodness-of-fit between each model.    
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We compared chemicals with available uterotrophic data in order to investigate the 
associations with ER Interaction Scores and in vivo rodent estrogenicity. Uterotrophic OECD 
guideline and EDSP T1S validation studies were used and chemical activity was classified 
consistently with Rotroff et al. (Rotroff et al. 2013b) as either being active or inactive for agonist 
or antagonist activity based on changes in rodent uterine weight. An additional comparison to 33 
ER reference chemicals from the EDSP21 working-group, obtained by expert review of the 
literature and NICEATM consensus, were compared to the ER Interaction Scores. Reference 
chemicals were classified for expected ER activity as strong, strong-moderate, moderate, weak, 
very weak/ agonist (metabolism required), or negative. ER Interaction Scores were binned by 
reference chemical categories, and the distributions were plotted as box plots. Each group of 
binned ER Interaction Scores was tested for significance using the Mann-Whitney U test. A 
binned group was considered statistically significantly different from another group if the Mann-
Whitney U test resulted in a p < 0.1. The overall trend was tested for significance by Kruskal-
Wallis one-way ANOVA. 
 
Results 
A total number of 1800 chemicals were available for modeling based on existing data 
from the assays in Table 4.1. Assays were split into four groups, binding, agonist, antagonist, and 
growth, depending on the type of estrogenic activity reported. Chemicals with composite scores 
> 0 were considered to be statistically significant for ER activity within the respective group 
based on these criteria. Overall, 50 (2.7%), 186 (10.3%), 109 (6.1%), 144 (8%) chemicals 
produced composite scores > 0 for CSbinding, CSagonist, CSantagonist, and CSgrowth, respectively. These 
scores resulted in a total of 305 (16.9%) chemicals with ER Interaction Scores > 0.  Chemicals 
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that produced composite scores > 0 in only a single group totaled 16, 107, 79, and 52 for 
CSbinding, CSagonist, CSantagonist, and CSgrowth, respectively. Chemicals with a composite score > 0 in 
at least one group are clustered in Figure 4.4. Clustering of all chemicals is shown in the inset of 
Figure 4.4 to demonstrate that the vast majority (83.1%) of chemicals do not show any activity in 
any group.  
The 15 chemicals with the highest ER Interaction Scores are tabulated in Table 4.2.  
These include a both known agonist and antagonist chemicals. 17α-estradiol, raloxifene 
hydrochloride, 4-hydroxytamoxifen, 17β-estradiol, and 17α-ethinylestradiol had ER Interaction 
Scores > 80. 5HPP-33 was the only chemical with both CSagonist and CSantagonist > 0, suggesting 
the possibility of antagonist and agonist activity. Most of the chemicals in this subset had both 
high ERα and ERβ scores indicating a strong affinity for both isoforms, but with some chemicals 
displaying slight selectivity.  
Linear Transformation 
In an effort to correct variability due to differences in assay technologies, we performed a 
linear transformation on the chemical concentrations in the agonist and antagonist groups. The 
model R2 values were used as a measure of goodness-of-fit to determine whether the 
transformation improved the overall model fit. Histograms of R2 values are shown in Figure 4.5, 
and were used to characterize the differences between transformed and non-transformed models. 
The distribution of R2 values across all chemicals was not improved for the agonist group after 
the linear transformation (p > .05). However, when only the chemicals with ER Interaction 
Scores > 0 were included in the distribution of agonist R2 values, there was a statistically 
significant improvement in R2 values for the linear transformed group (p < .0001). The 
antagonist group was not improved in either set, likely due to the fact that no weak ER 
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antagonist, active in both assays, was available for transformation. Therefore, the only 
transformation that would occur for the antagonist group would be at very low concentrations.   
Model Stability 
In order to test model stability, the model for the agonist group was run with a single 
assay removed, and repeated for all assays. No statistically significant differences (p < .01) in the 
correlations of CSagonist were observed by removing any assay in the agonist group (Figure 4.6).  
Removal of the OT_ERaERb_1440 assay resulted in the largest drop (2.3%) of chemicals with 
ER Interaction Scores > 0. This change was not statistically significant (p > .01) and the linear 
model between the group without the OT_ERa_ERb_1440 assay and all assays in the agonist 
group produced an R2 of 0.87, indicating that the inclusion of the OT_ERa_ERb_1440 assay 
contributed 2.3% of the active compounds in the chemical library. Removal of the 
Tox21_ERa_LUC_BG1_Agonist assay increased the number of overall active chemicals to 
14.1% from 12.3%.  The R2 between the model with all assays and this model was 0.77, and the 
two were not statistically significantly different (p=1).   
Agonist and Antagonist Comparisons 
Eight chemicals produced both CSagonist and CSantagonist > 0. For this subset, one also had 
significant CSbinding and four had significant CSgrowth.  The scaled composite scores for this subset 
of chemicals ranged from 9.62 -56.73 and 13.06 – 71.58 for CSagonist and CSantagonist, respectively. 
Most chemicals were not significantly active for both CSagonist and CSantagonist. The spectrum of 
activity from agonism to antagonism for all chemicals is presented in Figure 4.7. Estrogens, 17α-
estradiol, 17β-estradiol, 17α-ethinylestradiol, 17α-estradiol, and diethylstilbestrol were among 
the chemicals with the highest CSagonist.  Phytoestrogens, apigenin, daidzien, and genistein were 
also detected with scaled CSagonist of 70, 61.7, and 51.7, respectively.  
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ERα and ERβ Comparisons 
The OT_ERaERa_1440 and OT_ERbERb_1440 assays from the agonist group were used 
to investigate ERα and ERβ specific responses, respectively. The results of this analysis can be 
seen in Figure 4.8. A total of 13 chemicals demonstrated statistically significantly increased 
potency for ERα; however, only 3 of these chemicals had scaled CSagonist > 0. ER antagonists, 4-
hydroxytamoxifen, raloxifene hydrochloride, and clomiphene citrate demonstrated significantly 
increased potency for ERα, but did not have CSagonist > 0.  The ERα scores for 4-
hydroxytamoxifen, raloxifene hydrochloride, and clomiphene citrate were 69, 70.8, and 92, 
respectively, and ERβ scores were 23.4, 20.8, 65.6, respectively.  
A total of 62 chemicals demonstrated statistically significantly increased potency for 
ERβ, 26 of which had CSagonist > 0. Most of the chemicals that displayed increased potency for 
ERβ produced relatively low ER Interaction Scores with only 6 chemicals producing scores > 20. 
Dehydroepiandrosterone and silwet L77 had ER Interaction Scores of 47.2 and 25.6, 
respectively. Of the 62 chemicals significantly elevated for ERβ, dehydroepiandrosterone was 
the only chemical that produced an ERα score > 0. 
Comparison to In Vivo Uterotrophic Assay  
A subset of chemicals with in vivo data on estrogenic potential from uterotrophic studies 
are represented with their associated ER Interaction Scores in Figure 4.9. A total of 45 chemicals 
were available for analysis from 15 separate studies. Out of the 45 available chemicals, 23 were 
classified as negative, 12 as positive for agonist activity, 2 for antagonist activity, and 8 for both 
agonist and antagonist activity. Within this 45 chemical subset, 19 produced ER Interaction 
Scores of 0, of which 3 were classified as agonist or antagonist in the uterotrophic analysis. 
Atrazine and disulfiram were classified as ER antagonists in the uterotrophic analysis, and 
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pendimethalin was classified as an agonist. Furthermore, 7 compounds with ER Interaction 
Scores > 0 were classified as negatives in the uterotrophic analysis; however, these 7 chemicals 
are comprised within the lowest 9 ER Interaction Scores > 0 (Figure 4.9). Out of the 26 
chemicals with ER Interaction Scores > 0, 19 were classified as having estrogenic activity in 
uterotrophic studies. Lastly, out of the 19 chemicals with ER Interaction Scores of 0, 16 were 
classified as having no estrogenic activity in available uterotrophic studies.  
Comparison to ER Reference Chemicals 
Thirty three chemicals classified for estrogenic potential by literature review and expert 
opinion overlapped with the present chemical library and were used to assess the performance of 
the model (Figures 4.10 and 4.11). Reference chemicals were classified as strong (3), strong-
moderate (1), moderate (4), weak (14), very weak (3), and negative (8). One chemical, 
methoxychlor, was classified as very weak and requires metabolic activation.  Eight of the thirty 
three chemicals produced ER Interaction Scores of zero, and all were classified as negative in the 
reference. No chemicals classified as negative produced ER Interaction Scores > 0 (Figure 4.10). 
In order to quantitatively evaluate the performance of the model relative to the available 
ER reference chemical classifications, the distributions of ER Interaction Scores were compared 
for each reference classification group (Figure 4.11).   The negative group was statistically 
significantly different all other groups (p < 0.1). We also found a statistically significant 
difference between the weak group and the moderate, and strong groups (p < 0.1). The small 
sample sizes of some groups made statistical comparison challenging. However, a Kruskal-
Wallis test conducted with all the groups suggested a strong association between the reference 
chemical classifications and the ER Interaction Scores (p < .001). Overall, the present analysis 
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demonstrates that the ER Interaction Scores are concordant with known activities of ER 
reference chemicals (Figures 4.10 and 4.11).  
Discussion 
The present study describes a novel approach for incorporating multiple in vitro assays 
into a model capable of quantitatively determining chemical potential to interact with a given 
signaling pathway. The ER signaling pathway is an ideal candidate for demonstrating this 
approach, because multiple in vitro assays measuring different parts of the ER pathway are 
available for thousands of chemicals. Furthermore, a relatively well established list of reference 
chemicals and in vivo assay data are available to validate model predictions.  Lastly, there is 
current need for an ER predictive model that can help resolve the bottle-neck that exists for 
thousands of chemicals mandated for regulatory endocrine screening. The purpose of the ER 
Interaction Score is to provide a metric for ranking chemicals based on their potential to interact 
with ER regardless of agonist or antagonist tendencies, since some chemicals are not easily 
defined as such. The individual composite scores and assay characteristics can then be examined 
to investigate the specific activity associated with each chemical (e.g. agonist/antagonist, 
ERα/ERβ). 
Assay grouping was based on the type of activity that the assays are capable of detecting. 
Grouping assays that indiscriminately detect agonists and antagonists, with assays that only 
detect agonist activity would increase the overall uncertainty around the composite 
measurements. It was also thought that non-linear least squares regression would be more 
appropriate for modeling groups of assays with similar activity profiles. The grouping of assays 
for the agonist group was stable, with no single assay driving the overall conclusions (Figure 
4.6). Separating assays into specific groups based on activity profiles provides the advantage of 
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enhancing the individual assays strengths and down-weighting the impact of their weaknesses. 
For example, the ACEA_T47D_80hr_Positive assay, used to construct the growth composite 
curves, detects steroid hormones other than estrogens and also responds to mitochondrial 
disruptors (Rotroff et al. 2013a). In addition, the ER binding assays are susceptible to false 
positives from detergent compounds by displacement of the ligand by receptor denaturation, and 
these compounds can be indentified in the cluster that includes only the actives in the binding 
group (Figure 4.3).  
The impact of these ER false positives can be reduced by taking the intersection of 
chemicals with CSbinding, CSagonist, and CSgrowth > 0. The cluster that includes active compounds 
for all three of these groups includes known estrogenic compounds such as, estrone, daidzein, 
17α-ethinylestradiol, and many others (Figure 4.4) (Caldwell et al. 2012; Gutendorf and 
Westendorf 2001; Totta et al. 2005; Zhang et al. 2012). The assays in the binding group were 
only tested up to 50µM; therefore, it is possible that weakly active chemicals would be 
undetected with these assays alone. Non-ligand mediated ER receptor activation has been 
documented, although little is known about the ability of xenobiotics to operate through this 
mechanism (Tremblay et al. 1999; Zwijsen et al. 1998). It is possible that chemical activation of 
alternative signaling pathways may induce ER signaling via this mechanism, and it would be 
expected that these chemicals would cluster in this group as well.     
The two ER isoforms, ERα and ERβ, share a 96% homology between their two DNA 
binding domains. However, the ligand binding domains are only 58% homologous (Mosselman 
et al. 1996). Furthermore, activation of these two receptors produces different phenotypic 
outcomes (Gustafsson 1999; Kuiper et al. 1997; Pravettoni et al. 2007). The differences in 
phenotypic outcomes have been partially attributed to differences in the F-domains of the two 
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isoforms (Skafar and Zhao 2008). Limited information regarding the preference for ERα and 
ERβ by environmental chemicals exists; however some studies have investigated the ER 
selectivity for a small group of chemicals that overlap with the present chemical library. Paech et 
al. (Paech et al. 1997) investigated the ERα and ERβ selectivity of diethylstilbestrol, raloxifene, 
and tamoxifen. Diethylstilbestrol was not found to significantly prefer ERα or ERβ which is 
consistent with the present model scoring 71.4 and 78.06 for ERα and ERβ, respectively. The 
two selective estrogen receptor modulator (SERM) chemicals, raloxifene and tamoxifen were 
identified as being selective for ERα (Paech et al. 1997). Both raloxifene hydrochloride and 4-
hydroxytamoxifen had significantly elevated ERα scores relative to ERβ in the present model (p 
< .01). Genistein, apigenin, and daidzein are phytoestrogens that demonstrate increased affinity 
for ERβ relative to ERα, although they readily activate both receptors (Table 4.2) (Kuiper et al. 
1997; McCarty 2006; Muthyala et al. 2004). The present model did not find a statistically 
significant difference for the chemical selectivity of ERα and ERβ for these chemicals, but did 
find an increased affinity for ERβ for daidzein and genistein with ERα/ERβ scores of 56.6/74.5 
and 36.8/57.3, respectively (Table 4.2). Apigenin had high scores for both isoforms with an 
ERα/ERβ score of 100/86.5. Lastly, dehydroepiandrosterone (DHEA), a known estrogen agonist 
that readily binds to both ERα and ERβ, but with slightly greater affinity for ERβ was detected 
with an ER Interaction Score of 54.9 and an statistically significant increase for ERβ, with an 
ERα/ERβ score of 28.8/53.0 (Chen et al. 2005).  Although, only a small set of chemicals are 
available for comparisons, it appears that the scores are mostly consistent with the available 
literature. 
Uterotrophic assays are designed to measure estrogenic activity through increased uterine 
weight in immature or ovariectomized rats (Odum et al. 1997). This assay offers the most direct 
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mammalian in vivo measurement of estrogenicity of any of the regulatory EDSP T1S, and has 
been used to evaluate a relatively large number of chemicals compared to many other in vivo 
platforms. The studies used in this analysis were all performed to OECD guidelines allowing for 
more consistent comparisons across chemicals (Rotroff et al. 2013b).  Three chemicals, atrazine, 
disulfiram, and pendimethalin were classified as having uterotrophic activity and had ER 
Interaction Scores of 0. Atrazine was classified as an antagonist in the uterotrophic assay and is 
known to suppress estrogen synthesis through the inhibition of aromatase and does not act 
through the estrogen receptor; therefore, it would not have been expected to be detected in these 
assays (Roberge et al. 2004). Pendimethalin was not active in the 
Tox21_ERa_LUC_BG1_Agonist, Tox21_ERa_BLA_Agonist_ratio, or the 
OT_ER_ERaERa_1440 assays included in the agonist group; however, and due to the 
uncertainty around the concentration response curves the model was not considered statistically 
significant.  
We compared a subset of 33 reference chemicals with established estrogen activity to the 
ER Interaction Scores in order to quantitatively determine the predictive accuracy of the model 
(Figures 4.10 and 4.11). Out of the 33 chemicals, the model correctly classified 33/33 (100%) of 
the ER reference chemicals as active or inactive (Figures 4.10 and 4.11). Furthermore, the 
model’s ER Interaction Scores successfully ranked chemicals according to their reference 
activity profiles of strong, strong-moderate, moderate, weak, very weak, and negative (p = 9x10-
5) (Figures 4.10 and 4.11). 
The vast majority of chemicals included in this chemical library (83%) did not display 
indications of interacting with the ER signaling pathway, and would be low priorities for 
additional ER testing. If maximum sensitivity is desired, the model can be run with narrower 
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confidence intervals around the composite curves, resulting in increased overall false positives 
and decreased false negatives. However, based on the available reference chemical 
classifications and in vivo data, the present thresholds demonstrate very few occurrences of false 
positives or false negatives. (Figures 4.9, 4.10, 4.11). Besides the ability to test large numbers of 
chemicals at a reduced cost, this approach has some significant advantages over the traditional 
regulatory tests. Primarily, the assays are performed using human targets, and the measurements 
can be directly attributed to a target within a molecular signaling pathway. The advantage of 
measuring molecular events is that they can sensitively identify the potential for an adverse 
outcome, as opposed to the requirement of frank toxicity or an overt physiological change such 
as in traditional in vivo bioassays like the uterotrophic or 2-generation reproduction studies.   
This approach is amenable to the prioritization methods detailed in Reif et al. (Reif et al. 
2010, 2013). If the goal is to prioritize for risk assessment for ER, the ER Interaction Score can 
be used as a single slice in a ToxPi, with other slices composed of QSAR results and/or exposure 
information. The incorporation of exposure information into a ToxPi implementation has been 
previously described (Gangwal et al. 2012). If the goal is to rank chemicals based on endocrine 
disrupting potential, the ER Interaction Score could be used as a single slice in the ToxPi, with 
other slices composed of models covering additional MOA (e.g. neuroendocrine, thyroid, 
steroidogenesis, androgen). We propose the present model as an immediately available tool that 
is capable of ranking chemicals for potential interactions with ER and can be used to prioritize 
chemicals for EDSP T1S. The use of in vitro models can help to ensure that the chemicals 
entering EDSP T1S are the chemicals most likely to require regulatory action. Lastly, the present 
study offers the advantage of a large chemical library and many assays measuring orthogonal and 
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complimentary mechanisms to better assess the uncertainty around in vitro measurements and 
further elucidate ER biology. 
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Tables 
Table 4.1. ER In Vitro Assay Annotation and Model Grouping 
 
Map to 
Figure 
4.1 
Assay Name Assay Information Group 
1 NVS_NR_hER Human ER binding assay Binding 
1 NVS_NR_mERa Murine ERα binding assay Binding 
1 NVS_NR_bER Bovine ER binding assay Binding 
2 OT_ERaERa_1440_agonist Odyssey Thera ERα-ERα dimerization in agonist 
mode after 1440 minutes Agonist 
3 OT_ERa_ERb_480_agonist Odyssey Thera ERα-ERβ dimerization in agonist 
mode after 480 minutes Agonist 
4 OT_ERbERb_1440_agonist Odyssey Thera ERβ-ERβ dimerization in agonist 
mode after 1440 minutes    Agonist 
5 Tox21_ERa_LUC_BG1_Antagonist ERα luciferase reporter gene assay in human BG-1 
ovarian cells in antagonist mode  Antagonist 
5 Tox21_ERa_BLA_Antagonist_ratio ERα β-lactamase reporter gene assay in human HEK-293 cells in antagonist mode Antagonist 
6 Tox21_ERa_LUC_BG1_Agonist ERα luciferase reporter gene assay in human BG-1 
ovarian cells in agonist mode  Agonist 
6 Tox21_ERa_BLA_Agonist_ratio ERα β-lactamase reporter gene assay in human HEK-293 cells in agonist mode Agonist 
6 ATG_ERE_CIS Multiplexed ER reporter gene assay using full length 
receptor in HepG2 cells Agonist 
6 ATG_ERa_TRANS Multiplexed GAL4 reporter construct with  human ERα ligand-binding domain in HepG2 cells. Agonist 
7 ACEA_T47D_80h Cell growth using real-time cell analysis in T47D 
cells at 80 hours  Cell Growth 
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Table 4.2. 15 Chemicals with Highest ER Interaction Scores   
CASRN Chemical Name 
Scaled Composite Score ER 
Interaction 
Score 
Agonist 
ERα 
Score 
Agonist  
ERβ 
Score Binding Agonist Antagonist Growth 
82640-04-8 Raloxifene hydrochloride 86.64 0.00 100.00 0.00 93.32 70.78 20.81 
57-91-0 17α-Estradiol  94.93 88.03 0.00 76.90 86.62 71.43 75.46 
68392-35-8 4-Hydroxytamoxifen  84.61 0.00 81.06 0.00 82.84 68.99 23.41 
50-28-2 17β -Estradiola  83.67 100.00 0.00 62.17 81.95 68.23 67.87 
57-63-6 17α-Ethinylestradiol 99.41 92.87 0.00 49.12 80.47 70.56 65.63 
84-16-2 meso-Hexestrol 99.93 82.23 0.00 54.59 78.92 68.17 68.72 
56-53-1 Diethylstilbestrol 98.56 85.20 0.00 46.64 76.80 71.43 78.06 
50-41-9 Clomiphene citrate 80.53 0.00 60.45 0.00 70.49 92.03 65.57 
50-28-2 17β-Estradiolb 100.00 87.50 0.00 23.45 70.32 71.73 76.90 
1478-61-1 Bisphenol AF 93.19 59.16 0.00 57.38 69.91 47.42 57.27 
53-16-7 Estrone 90.09 63.77 0.00 55.40 69.76 47.75 49.38 
486-66-8 Daidzein  56.83 61.74 0.00 89.26 69.28 56.59 74.50 
131-55-5 
22'44'-
Tetrahydroxybenz
ophenone 
70.49 79.62 0.00 46.76 65.62 55.26 60.58 
105624-86-0 5HPP-33 74.60 51.30 38.43 62.70 62.87 100.00 86.53 
50-27-1 Estriol 83.26 46.58 0.00 54.33 61.39 56.19 39.90 
aTested at concentrations up to 3.8µM; bTested at concentrations up to 200µM 
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Figures 
Figure 4.1. ER Signaling Pathway Overview (Overlayed with ToxCast Assays). Schematic of ER 
signaling pathway used to define model groupings. Numbers identify molecular events with 
available ToxCast assays, and correspond to the assays in Table 4.1. 1 corresponds to the binding 
group; 2,3,4,6 correspond to the agonist group; 5 corresponds to antagonist group; 7 corresponds 
to growth group. Cell proliferation was identified as a functional endpoint of ER activation. 
Available assays measure events covering several possibilities for a chemical to either upregulate 
or downregulate ER activity. 
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Figure 4.2. Graphical Representation of the Logical Structure of the Model. The initial step is performed to group assays according to 
the disjunctive logic of the model signaling pathway in Figure 4.1. Second, composite curves are fit using all available data within 
each group to model the overall concentration response. Next, composite scores are clustered to identify chemicals with similar 
activity profiles among groups. ER Interaction Scores are then calculated from the composite scores in each group to rank chemicals 
according to estrogenic likelihood. Lastly, individual assays and composite scores are investigated for additional ER characteristics 
(agonism/antagonist, ERα/ERβ activity).    
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Figure 4.3. Composite Curve Example. A) The concentration response curves for all available assays included in the agonist group. B) 
The composite model of all the individual concentration response curves from the agonist group for bisphenol-A. The lower window 
of the model confidence interval is used to calculate the efficacy score, and first concentration for which the lower window of the 
confidence interval that does not overlap with zero is assigned the LEC. The percentage across all tested concentrations that the LEC 
occurs is the Potency Score. If both the Potency and the Efficacy Score > 0, then the mean of the Potency and Efficacy score is 
assigned as the Composite Score for that group. If the AC50 occurs after the LEC then it is blue and considered to be significant, 
otherwise it is colored gray.     
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Figure 4.4. Heatmap of Composite Scores. The scaled composite scores are clustered using Euclidean distance and Ward’s method. 
Rows are groups of assays and columns are chemicals with at least one scaled composite score > 0. The colors represent the scaled 
composite scores (0-100). Clusters of activity provide evidence for which mechanisms are being activated along the ER signaling 
pathway. For example, chemicals with scaled composite scores > 0 for only the growth group are likely to be activating a non-ER 
mediated cell proliferation pathway. Chemicals with scaled composite scores > 0 for binding, agonist, and growth groups are likely to 
be capable of ligand mediated ER activation.  The inset is the clustering of the entire chemical library to provide context for the ratio 
of inactive chemicals to active chemicals.
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Figure 4.5. Impact of Linear Transformation on the Distributions of R2. A) The distributions of 
R2 values for all chemicals in the agonist and antagonist groups without linear transformation. B) 
The linear transformation provided little change to the R2 values in the antagonist group and 
slightly lowered the R2 values in the agonist group across all chemicals. C) The distribution of R2 
values for only the active chemicals (composite scores > 0) without linear transformation were 
similar to the distributions of all chemicals. D) However, the R2 values for only the active 
chemicals were significantly improved after linear transformation (p < .0001). This result 
suggests that the linear transformation reduced the error associated with active compounds. No 
weak reference chemical was available for linear transformation of the antagonist group, 
therefore only very potent compounds would have been adjusted. This limitation explains the 
lack of change in the distribution of R2 values for this group. 
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Figure 4.6. Agonist Model Stability. Because the agonist group contains the largest number of 
assays, an assessment was conducted to determine the contribution of each assay to the overall 
number of active chemicals.  The percentage of active chemicals for all assays in the agonist 
group, and with the removal of a single assay is shown. The percentage of active chemicals is the 
most greatly reduced by removing the OT_ERaERb_1440 assay, however this difference is not 
statistically significant. The R2 and p values correspond to the linear regression between the 
composite scores between all assays included and the removal of individual assays. Overall, no 
single assay in the agonist group significantly contributed to the overall number of active 
chemicals.
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Figure 4.7. Agonist/Antagonist Volcano Plot. Agonist and antagonist activity was plotted 
with the ER Interaction Score on the y-axis and CSagonist and CSantagonist on the x-axis. 
Chemicals with high ER Interaction Scores and high CSagonist fall to the upper right quadrant, 
whereas chemicals with high ER Interaction Scores and high CSantagonist are located in the 
upper left quadrant. The colors are determined by the potency of the LEC value. Some 
chemicals may have a high ER Interaction Score driven partially by their efficacy relative to 
another chemical’s more potent response. The chemicals in the middle of the x-axis with ER 
Interaction Score > 0 had no significant activity in either the agonist or antagonist groups, but 
were active in the binding assay group Interaction Score > 0 had no significant activity in 
either the agonist or antagonist groups, but were active in the binding assay group. 
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Figure 4.8. ERα/ERβ Volcano Plot. ERα and ERβ activity was plotted with the CSagonist on 
the y-axis and the ERα Potency Scores and ERβ Potency Scores on the x-axis. Chemicals 
with high CSagonist and high ERα scores fall to the upper right quadrant, whereas chemicals 
with high CSagonist and high ERβ scores fall towards the upper left quadrant. The colors are 
determined by the CSbinding. The dashed lines represent 3 σ from the mean. Any chemical 
outside the dashed lines was considered to show statistically significant increases in activity 
for either ERα or ERβ. As expected 17β-estradiol and diethylstilbestrol showed no 
preference for either isoform, and daidzein and genistein were active for both ERα and ERβ, 
but showed a slight preference for ERβ. 
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Figure 4.9. Uterotrophic Analysis. A chemical subset with uterotrophic data was plotted with 
the ER Interaction Score on the y-axis and the CSagonist and the CSantagonist on the x-axis. 
Chemicals with high ER Interaction Scores and high CSagonist fall to the upper right quadrant, 
whereas chemicals with high ER Interaction Scores and high CSantagonist are located in the 
upper left quadrant. Uterotrophic classifications were obtained from Rotroff et al. (2013b) 
and annotated as either being negative, positive for agonist activity, positive for antagonist 
activity, or both.  
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Figure 4.10. Reference Chemical Analysis. A chemical subset with ER reference chemical 
classifications was plotted with the ER Interaction Score on the y-axis and CSagonist and the 
CSantagonist On the x-axis. Chemicals with high ER Interaction Scores and high agonist 
composite scores fall to the upper right quadrant. Reference chemical classifications were 
determined by expert review of the literature and NICEATM consensus. 25 of the 33 
reference chemicals were classified as ER actives, and 24 were predicted to have ER activity 
with ER Interaction Scores > 0.  Progesterone and Haloperidol were predicted as having very 
weak activity, but were classified as negatives in this reference set. 
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Figure 4.11. Quantitative Reference Chemical Analysis. ER model performance was 
quantitatively evaluated by comparing the ER Interaction Scores of subset of 33 ER 
reference chemicals with their associated reference classifications. Reference chemicals were 
classified as strong, strong-moderate, weak, very weak, or negative according to expert 
literature review and in consensus with NICEATM evaluations. Limited numbers of 
chemicals for comparison made the statistical analysis challenging; however, the ER 
Interaction Score significantly distinguished the negative group of chemicals from the very 
weak, weak, moderate, and strong classifications. A highly significant overall trend was 
detected between ER Interaction Scores and reference chemical classifications (p< .0001). 
The colors of the boxplots correspond to their data points in Figure 4.10. 
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CHAPTER 5 
GENERAL DISCUSSION 
The implications of endocrine disruption carry a wide range of possible adverse 
health effects. The realization of sensitive toxicological targets capable of disrupting 
endocrine physiology, and the increased incidence of reproductive and developmental 
abnormalities, has led to a major effort to characterize the risk of endocrine disruption by 
environmental chemicals (Auger et al. 1995; Carlsen et al. 1992; Skakkebaek et al. 2001; 
Toppari et al. 2010). However, the current regulatory screening tests are time consuming, 
require significant animal resources, and are prohibitively expensive to generate regulatory 
decisions for all the chemicals mandated for testing (National Research Council 2007; U.S. 
EPA 2011). The present body of work makes a large library of in vivo data for phenotypic 
anchoring available, describes approaches for identifying modes-of-action (MOA) with the 
potential for successful predictive models, in vitro assay assessment and characterization, and 
construction of a predictive model capable of identifying chemicals with estrogenic potential. 
Advances in In Vitro Technology  
Technological advances are making the generation of biological data faster and 
cheaper with high-throughput in vitro assays, in silico approaches, and –omics technologies 
(i.e. genomics, metabolomics, and proteomics). These advances are creating new 
opportunities for chemical safety assessment and improving our understanding of the 
molecular complexity underlying the adverse effects observed in traditional bioassays.  
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Advantages of HTS assays include the ability to test thousands of chemicals in weeks rather 
than years. However, with enormous amounts of data generated by this technology, new 
methods for data analysis and data interpretation must be developed. 
A key component to the shift from in vivo to in vitro technology for hazard 
determination is the shift from observing adverse phenotypic effects in a whole-animal 
context, to observing molecular changes in a cellular context. One advantage to using HTS 
assays is that changes in molecular events can be detected more sensitively than identifying 
overt toxicity. HTS assays measuring changes in transcriptional activation/suppression are 
thought to be measuring one of the earliest cellular changes in an adverse response (Beyer et 
al. 2007). The ability to sensitively measure these changes can allow for experiments to be 
conducted at more realistic exposure levels than many traditional toxicology tests, which rely 
on measurements of overt toxicity from high doses. However, this technology comes with 
certain disadvantages and challenges. One of the challenges is that chemical induction or 
suppression of a molecular target does not necessarily constitute a step toward an adverse 
outcome (Beyer et al. 2007). The ER Interaction Score for genistein (61.1) is close to the ER 
Interaction Score of diethylstilbestrol (81.1) (as described in Chapter 4). However, 
diethylstilbestrol is a pharmaceutical that was removed from the market due to the 
debilitating effects it caused to fetal development, whereas, genistein is naturally occurring in 
soy and is in products consumed globally (Palmlund et al. 1993; Toppari et al. 2010). In 
addition, 17β-estradiol, an endogenous estrogen with an ER Interaction Score of 85.8, and is 
present in females in relatively high concentrations and is critical to wellbeing. There is 
nothing intrinsically adverse about the activation of ER, it is however, potentially adverse for 
a chemical to interfere with the tightly regulated estrogen signaling network. Chemicals that 
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preferentially bind to ERα may also pose an increased hazard compared to chemicals the 
preferentially bind ERβ. Unlike ERα, ERβ activation is actively being explored for its 
potential anti-inflammatory and chemotherapeutic properties upon activation (Warner and 
Gustafsson 2010).  
Phenotypic Anchoring 
Because not all changes in bioactivity, represented by in vitro perturbations, indicate 
an increased hazard upon chemical exposure, it is important to identify which changes in 
bioactivity can serve as biomarkers for adverse outcomes. An example where gene 
expression profiling technology was successfully implemented in order to classify 
compounds based on their toxicological MOA can be seen in the work by Thomas et al. 
(Thomas et al. 2001). This study used cDNA microarrays to classify 24 well characterized 
chemicals into classes of peroxisome proliferators, AhR agonists, noncoplanar PCBs, 
inflammatory response activators, and hypoxia signal transduction pathway activators. The 
data was modeled using naïve Bayesian classification with cross-validation, and the results 
identified 12 transcripts that classified chemicals with an estimated 100% accuracy for the 
represented toxicological classes (Thomas et al. 2001). Several of the transcripts 
systematically identified as being significant, have known involvements in toxicological 
pathways, such as CYP1A2 which is regulated by the aryl hydrocarbon receptor (AhR) 
(Schmidt and Bradfield 1996). 
Using genomics for identifying potential endocrine disrupters is challenging because 
of the large number of genes regulated by activation of hormone receptors. A study by Hah et 
al. (Hah et al. 2011) identified that the ER activated ~ 26% of the transcriptome in MCF-7 
cells. ER also has a number of non-genomic mechanisms including ERK and Src 
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phosphorylation, which upon activation did not result in cellular proliferation in MCF-7 cells 
(Harrington et al. 2006). These results suggest that the adverse proliferative response of 
estrogens in certain cancers is due to the genomic mechanisms of ER activation (Harrington 
et al. 2006). As HTS data continues to be generated on a large scale, tools must be developed 
in order to perform phenotypic anchoring to determine predictivity for these in vitro 
endpoints.  ToxRefDB is database capturing decades of legacy toxicity data from regulatory 
testing and is an available tool for phenotypic anchoring of HTS assays (Martin et al. 2009b, 
2009a).  Additional work by Martin et al. (Martin et al. 2011) and Knudsen et al. (Knudsen et 
al. 2009) have demonstrated that HTS assays can be used to successfully predict certain 
effects in traditional toxicology bioassays. 
Previous work to identify relationships between chemical induced, endocrine effects 
observed in vitro could only be linked to in vivo effects for a very limited number of 
chemicals. The data included in Chapter 2 makes in vivo data available for a wide range of 
endocrine assays, and allows for easy aggregation and segregation of assay characteristics 
based on the resolution desired for modeling efforts. The present body of work demonstrates 
that HTS estrogen and androgen assays can be used as measures of bioactivity that can 
classify chemicals similarly to regulatory endocrine assays for estrogen and androgen MOA, 
respectively (as described in Chapter 2). Effects observed in OECD guideline and EDSP T1S 
validation studies were used to accomplish the phenotypic anchoring. Relative to other 
available HTS assays, the hypothesized estrogen and androgen HTS assays, measuring 
receptor binding and activation, were determined to be more informative for chemicals that 
caused adverse effects in the available estrogen and androgen in vivo assays. Overall, this 
indicates that active chemicals in estrogen and androgen in vitro assays, tend to also cause 
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adverse effects in in vivo endocrine assays. In addition, available HTS assays may not be 
sufficient for anchoring to some endocrine phenotypes, such as those produced by affecting 
thyroid and steroidogenesis MOA (as described in Chapter 2). Many chemicals thought to 
alter thyroid hormone homeostasis leading to adverse effects are thought to be caused by 
chemically induced changes in thyroid hormone metabolic clearance; however, many HTS 
assays measuring these endpoints are active for chemicals lacking an association with thyroid 
toxicity (Saghir et al. 2008; Zorrilla et al. 2009).     
Combining In Vitro Data to Test for In Vivo Effects 
Previous efforts comparing chemical effects in multiple in vitro assays do so by 
aggregating across AC50 values or dichotomizing assay results (Rotroff et al. 2013; Schenk 
et al. 2010). Although, these analyses perform well for classifying chemicals for activity or 
comparing assays across MOA, they do not allow for quantitative rankings of predicted 
chemical activity. In addition, the dose-response context is lost when assay results are 
dichotomized. Every in vitro and in vivo assay has certain limitations and shortcomings. 
Some in vitro assays lack sensitivity, generating false negative results, or may be prone to 
false positive results. The ER binding assays used in the present work indicate that these 
assays were less sensitive when compared to the transcriptional factor and cell growth assays 
(as described in Chapter 3). Because of limitations within the assay technology, chemicals 
could not be tested above 50 µM, providing no information about chemicals that were active 
above these concentrations. The ER binding assays are also susceptible to false positives by 
detergent compounds that cause denaturation of the receptor, making it appear as if the 
natural ligand was displaced due to the test chemical. However, most of the chemicals that 
were active in the ER binding assay were also active in the other ER assays (as described in 
 146
Chapter 3 and Chapter 4). The T47D cell growth assay is not specific for ER activity and 
responds to other steroid hormones and mitochondrial chain disrupters. If one was to rely on 
this single assay to prioritize chemicals for more resource intensive assays, then too many 
false positives for ER would be tested and resources would be wasted. Alternatively, if the 
ER binding assay was the only assay used to prioritize chemicals for endocrine screening, a 
significant number of ER agonists would go undetected.  Because assays technologies have 
different sensitivities, one way to reduce the noise that occurs when comparing multiple 
technologies is to perform a linear transformation of the test concentrations. Ideally, this 
transformation will correct for noise that occurs from the technology platform, and the 
remaining difference in responses can be explained biologically. This can be observed by the 
improvement in R2 values of active chemicals in the agonist group after performing the linear 
transformation (p < .0001) (as described in Chapter 4).    
An important aspect to reducing the statistical noise that occurs when associations are 
made across a large number of predictor variables is to perform a method of dimensionality 
reduction. Simply applying machine learning methods to a large set of in vitro assays to 
identify associations with in vivo endpoints limits the likelihood that the model will have 
enough statistical power to detect a predictive signature (Thomas et al. 2012).  The use of 
multiple in vitro assays in a model that emphasizes their strengths and minimizes their 
weaknesses will further reduce the noise around their measurements and enhance the 
possibility of a strong predictive signal.  One method of combining in vitro assays to predict 
active chemicals in multigenerational reproductive studies was explored by Martin et al. 
(Martin et al. 2011). In vitro assays with a univariate association with reproductive endpoints 
were linked to gene sets, reducing the dimensionality and enhancing the predictive capability 
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of the model (Martin et al. 2011). For modeling effects of ER signaling, assays were assigned 
to four groups according to assay characteristics for detecting estrogens and anti-estrogens 
and according to location of their respective mechanism on the branch of the ER signaling 
pathway (as discussed in Chapter 4). For example, the ER binding assays readily but 
indistinguishably detect agonists and antagonists. The grouping of this assay with agonist-
specific assays would result in increased uncertainty for antagonist compounds in the agonist 
assays. Incorporating prior knowledge and reducing dimensionality can aid in the 
construction of successful predictive model.  
Appropriate in vivo assays and reference chemical libraries must also be available to 
effectively characterize the in vitro assay endpoints under investigation.  For example, 
multigenerational reproductive studies can detect estrogenic compounds; however, they also 
detect androgen and thyroid disrupting compounds, among other MOA. The uterotrophic 
assay is intended to be an assay targeted for detection of chemicals that mimic estrogen or 
affect estrogen synthesis (Odum et al. 1997). The uterotrophic assay has also been conducted 
on a relatively large set of chemicals and has a validated protocol to promote consistency 
across studies. Lastly, a validated list of ER reference chemicals exists to anchor model 
predictions, making ER an ideal candidate to demonstrate the effectiveness of combining 
concentration response data for prediction of estrogenic potential. The results indicate a high 
degree of concordance between increasing model ER Interaction Scores and activity in 
uterotrophic studies as being highly associated with ER reference chemicals (p < .0001) (as 
described in Chapter 4). The ER Interaction Scores can be ordered to rank chemicals with a 
high probability to a low probability of interacting with ER.  
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One advantage to the current approach is that it can be re-evaluated with new 
technologies as they become available. As research continues to refine the signaling pathway 
for ER, the assay-grouping logic can also be updated to improve the overall biological 
relevance of the model. The methods are also extendable to other pathways that have 
orthogonal assay technologies and a common positive control.  The work herein describes a 
generalizable approach for conducting a comparative analysis that is capable of identifying 
MOA for in vitro predictive modeling, methods for characterizing the strengths and 
weakness for in vitro assays for the purpose of model optimization, and a novel approach for 
combining concentration response data into a pathway-based model capable of predicting 
chemicals with estrogenic potential.  
Limitations 
As with any computational model or biological assay, limitations exist and are 
important for defining the appropriate domain of applicability.  In vitro technologies measure 
molecular events and provide measures of bioactivity, unlike in vivo assays that provide 
phenotypic outcomes without the mechanistic context. The in vitro assay results in this body 
of work, represent molecular initiating events of key targets involved in endocrine MOA; 
however, a chemical’s activation of any of these targets does not indicate that exposure to 
this chemical would result in an adverse outcome. Furthermore, in vitro assays are limited in 
their ability to account for the effects of chemical metabolism and other pharmacokinetic 
properties. Although, efforts to incorporate pharmacokinetic information into a high-
throughput platform have been investigated, continued efforts are needed in order to be able 
to apply these methods to diverse chemical libraries (Rotroff et al. 2010; Wetmore et al. 
2012). For any loss-of-signal in vitro assays, such as the antagonist assays used herein, 
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confounding by cytotoxicity is a significant challenge. Although filtered for cytotoxicity, it is 
difficult to distinguish the weak antagonistic responses in the antagonist assays from early 
cytotoxic responses.   
A major challenge to validating predictive models for their predictive capability is the 
limited in vivo data available. Because a relatively few number of chemicals have been run in 
in vivo studies, an appropriate external validation set is not available. In Chapter 2, the open 
literature was used as an external validation set; however, these studies vary greatly in study 
quality and study design. The low number of chemicals available for comparison could result 
in a model that is overfit, for example the HTS-A model produced a balanced accuracy for 
guideline androgen studies and Hershberger studies of 0.92 and 1, respectively; however, 
these results were no longer statistically significant in the open-literature analysis (as 
described in Chapter 2). The decrease in predictivity in the open-literature could be due to 
either overfitting of the model, or because the external validation set was not representative 
of the original test set. As additional data becomes available from EDSP T1S, the analysis 
can be reevaluated to provide further validation of the models. 
The analysis in Chapter 3 details an approach for characterizing and assessing the 
applicability of multiple ER in vitro assays. A major limitation of the cell type, used to assess 
ER related induction of cell growth, is that the T-47D cells express additional hormone 
receptors that upon activation can impact cell growth and cell morphology. Furthermore, this 
assay responds to mitochondrial disrupters (as described in Chapter 3). Once again only a 
limited amount of chemicals were available for comparison in vivo and ER reference 
chemical comparisons, 29 and 25 chemicals respectively. However, this cell line readily 
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responds to estrogens and when used in conjunction with other ER assays, can be used to 
confirm a functional change.  
  The in vitro limitations (e.g. metabolism, not necessarily adverse) are also relevant 
to the modeling results in Chapter 4. In addition, the ER Interaction Score is scaled relative to 
the other chemicals in the model. The addition of new chemicals would not change the 
composite score, but would change the scaled composite score and the subsequent ER 
Interaction Score. The assays (features) that were selected for the ER model are based on the 
hypothesis in Chapter 2, that assays measuring ER activation are predictive for estrogen 
related effects observed in vivo. Permutation demonstrated that these assays were 
significantly more informative than other assays for estrogen related effects in vivo (as 
described in Chapter 2).The assay used in the model, and subsequently the model itself, does 
not take into account chemicals that may alter estrogenic action through interfering with 
neuroendocrine mechanisms or estrogen biosynthesis. These compounds would be detected 
in the in vivo estrogen studies, but would be missed with the current approach. Additional 
models measuring effects on steroidogenesis are needed in order to detect these chemicals. 
The logic used to calculate the ER Interaction Score is based on the pathway illustrated in 
Figure 4.1, and other mechanisms or pathways may not be accounted for that would impact 
the ER Interaction Score calculation.  
The ER model, presented in Chapter 4, was developed using only in vitro data and 
was not trained on any external dataset; therefore, the problem of overfitting, such as those 
experienced with traditional machine learning algorithms, are not particularly applicable. 
Although, classic overfitting may not be a major concern, there is a high degree of 
collinearity between the ER in vitro assays. The addition of other ER assays may 
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significantly change model outcome. Furthermore, the assumptions for deriving activity 
thresholds of individual assays and the thresholds for significance of the model’s confidence 
and prediction intervals may not be optimal. Most of the data available for evaluating the 
performance of the ER model is based on effects observed in rodent studies. It is likely that 
species differences exist that could confound the results observed in the model validation (as 
described in Chapters 2 and 4). The model showed strong predictive performance against the 
available ER reference chemicals; however, this chemical set is relatively small and may not 
account for all mechanisms of ER activation. Furthermore, this reference set overrepresents 
active chemicals (76% actives). It is possible that with a larger reference set with equal 
numbers of active and inactive chemicals the model evaluation would have been altered. 
However, this reference set is only used to evaluate the model and not to train the model, and 
therefore should have a minimal impact on the model efficacy. 
As with any model, limitations exist and must be evaluated in the context for which 
the model is intended. The new in vivo data that will become available throughout EDSP T1S 
can be extremely valuable in supplementing the currently available in vivo data. New 
technologies capable of determining metabolic potential in an HTS format are needed to 
improve the in vivo relevance of predictive models. Until these resources are made available, 
it is important that the results reported in the present body of work are taken in the context of 
these limitations.    
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CHAPTER 6 
FUTURE DIRECTIONS 
The development of a model capable of prioritizing chemicals based on their 
estrogenic likelihood provides and an important step towards assessing the endocrine 
disrupting potential for hundreds of environmental chemicals. The economic burden of 
testing all chemicals mandated for endocrine screening in medium- and low-throughput 
assays has made computational models of in vitro and in silico assays an optimal tool to 
facilitate the testing of these chemicals. Additional work to refine current assays and models 
is needed, and new assay technologies capable of alleviating the current limitations with in 
vitro technology will be required in order to fully transform the current state of toxicological 
safety assessment. 
Assay and Model Development to Address Biological Gaps 
 The comparative analysis in Chapter 2 identified the available thyroid and 
steroidogenesis assays as being inadequate for classifying chemicals consistently with the 
EDSP T1S assays measuring thyroid and steroidogenesis mechanisms (as described in 
Chapter 2). Currently, the ToxCast assay library consists of only a single, aromatase enzyme 
inhibition assay. Although this is an important component of steroid biosynthesis, regulating 
the conversion of estrogens to androgens, there are many additional ways a chemical can 
target steroid biosynthesis including CYP11A1 and CYP17 (Zhang et al. 2005). Currently, 
efforts are underway to develop a quantitative assay measuring multiple steroid hormones 
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along the steroidogenesis pathway in a 96-well format using H295R cells (Hecker et al. 
2006; Zhang et al. 2005). Once the data from this assay becomes available, computational 
modeling within the framework of the steroidogenesis pathway will need to be developed 
and the predictive capability will need to be demonstrated.  
 Thyroid toxicity is a particularly difficult endpoint to screen using in vitro assays. No 
association was observed with chemicals that caused thyroid toxicity in the EDSP T1S 
guideline studies and the HTS thyroid hormone receptors assays (as discussed in Chapter 2). 
These results suggest that most chemicals known to cause thyroid toxicity are not mediated 
through the thyroid hormone receptor. Other in vitro assays measuring thyroid function exist, 
but most of these are thyroid explants assays and are not high-throughput (Hornung et al. 
2010). Additional studies have suggested that increased clearance of thyroid hormone by 
metabolic enzymes after chemical exposure can result in thyroid toxicity (Saghir et al. 2008; 
Zorrilla et al. 2009). HTS assays for liver metabolizing enzymes are available, and are 
generally active for thyroid disrupting compounds; however, they are oftentimes active for 
many chemicals with no evidence of thyroid toxicity limiting their predictive capabilities (as 
described in Chapter 2). Therefore, additional HTS need to be developed that can target more 
toxicologically relevant thyroid endpoints.   
 The androgen MOA is one with many available HTS assays that would be highly 
amenable to the approach described for ER. The Hershberger assay is an ideal in vivo assay 
to use for phenotypic anchoring of the HTS androgen assays.  One challenge with AR is that 
many adverse effects from xenobiotics are observed by antagonizing AR. Available AR 
antagonist assays exist within ToxCast, but because they are a determined through the loss of 
a fluorescent signal are prone to confounding by cytotoxicity.      
 157
Providing In Vivo Context 
 Ultimately, a chemical risk assessment must result in an estimated level of exposure 
that is presumed to be safe for the human population. A challenging aspect to interpreting in 
vitro assay results relative to the in vivo outcomes is the lack of absorption, metabolism, 
digestion and excretion in in vitro and in silico models. Chemicals that display activity in 
vitro may be rapidly metabolized and excreted, resulting in no adverse outcome observable in 
vivo. Conversely, a chemical may not be active in vitro but come active after metabolism in 
vivo. The conversion of in vitro activity concentrations to a human oral equivalent dose has 
been previously conducted (Rotroff et al. 2010; Wetmore et al. 2012). These studies 
identified that incorporating metabolic clearance and plasma protein binding provides 
estimates that can accurately estimate human oral equivalent doses. However, this method 
assumes 100% absorption by the gastrointestinal tract and is limited by the analytical 
methods that exist for only a subset of chemicals. Additional research is needed in this area 
to further refine this model and to make it widely available for in vitro based risk assessment.  
Potential for Prioritization and Targeted Testing 
 The near-term goal of EDSP21 is to prioritize chemicals for endocrine screening in 
the EDSP T1S by using computational and molecular-based in vitro assays (U.S. EPA 2011). 
The present model serves as one method for ranking chemicals based on in vitro activity for 
estrogenic potential and could be used as a component in a chemical prioritization. Because 
of limitations in cell-based assays (e.g.solubility), not all chemicals mandated for EDSP T1S 
will be able to be modeled using the approaches described herein. Quantitative structure-
activity relationship (QSAR) models have been demonstrated to effectively predict chemicals 
with the potential to bind to ER, and may be a valuable way to augment the current in vitro 
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limitations (Agatonovic-Kustrin et al. 2011; Li and Gramatica 2010). Another important 
component for prioritization is chemical exposure. Chemicals with a high likelihood of 
estrogenic activity, and a high risk of exposure should constitute a higher ranking in a 
prioritization scheme compared to a chemical with high likelihood of estrogenic activity, but 
negligible risk of exposure (Gangwal et al. 2012).   
 The intermediate-term goal of the EDSP21 is to replace some more resource intensive 
assays with computational models using in silico and in vitro approaches, or use these 
models so that certain assays may be opted out/in. The analysis presented in Chapter 4 
demonstrates that the present ER model predicts chemicals active in uterotrophic assays with 
a high degree of accuracy.  Additional information regarding impacts on estrogen 
biosynthesis and metabolic potential will be needed to effectively replace the uterotrophic 
assay. The uterotrophic assay is considered to measure a single MOA (estrogenic effects), 
other multi-modal assays will require additional models covering other MOA besides 
estrogenicity before a negative result would be sufficient to opt out of a particular EDSP T1S 
assay. For example, the pubertal female detects effects on the HPG axis, estrogen, thyroid 
and steroidogenesis (U.S. EPA 2007, 2012).  
 The shift towards the increased use of HTS assays for informing regulatory decisions 
should be viewed as an “improvement to toxicity testing rather than alternatives to animal 
testing” (Andersen and Krewski 2009). HTS assays offer some critical features not offered 
by traditional in vivo assays, namely throughput, sensitivity, cost, and human relevance 
(National Research Council 2007). In vivo assays offer the determination of adverse 
outcomes and a multi-organ system for chemical assessment. Currently neither approach 
offer a superset of features, but the two can complement each other. Ideally, the purpose of 
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the prioritization scheme would be to make sure that the only chemicals being tested in the 
more resource intensive EDSP T1S assays are active for their respective MOA.  
The framework for endocrine disruption screening needs to be able to maximize the 
strengths and minimize the weaknesses of both the computational and in vivo approaches. As 
the computational models improve and develop to a superset of features for certain in vivo 
assays, then replacement of the in vivo assays will be necessary. The endocrine screening 
effort will require many years to effectively screen all the chemicals mandated for testing, 
technology will continue to evolve during this time, and the framework for testing needs to 
be flexible to accommodate improved and validated technologies as they become available. 
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